Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
25,400 | 2018-07-27 00:00:00 UTC | Health Care Sector Update for 07/27/2018: SGEN,NBRV,ABBV,TNXP | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-07272018-sgennbrvabbvtnxp-2018-07-27 | null | null | Top Health Care Stocks
JNJ +0.97%
PFE +0.73%
ABT -0.64%
MRK -0.77%
AMGN -0.52%
Health care stocks declined Friday, including a nearly 0.4% retreat for the NYSE Health Care Index in late trade. Also, shares of health care companies in the S&P 500 were down over 0.7% as a group while the Nasdaq Biotechnology index was fa... | In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon despite the drugmaker reporting above-consensus Q2 financial results and raising its FY18 earnings outlook. Excluding one-time items, AbbVie earned $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus by $0.03 per... | Excluding one-time items, AbbVie earned $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus by $0.03 per share and $60 million, respectively. In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon despite the drugmaker reporting above-consensus Q2 financial results a... | In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon despite the drugmaker reporting above-consensus Q2 financial results and raising its FY18 earnings outlook. Excluding one-time items, AbbVie earned $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus by $0.03 per... | Excluding one-time items, AbbVie earned $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus by $0.03 per share and $60 million, respectively. In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon despite the drugmaker reporting above-consensus Q2 financial results a... |
25,401 | 2018-07-27 00:00:00 UTC | Noteworthy Friday Option Activity: SBUX, ABBV, ZBH | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-sbux-abbv-zbh-2018-07-27 | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Starbucks Corp. (Symbol: SBUX), where a total volume of 68,276 contracts has been traded thus far today, a contract volume which is representative of approximately 6.8 million underlying shares (given that e... | Particularly high volume was seen for the $90 strike call option expiring July 27, 2018 , with 2,202 contracts trading so far today, representing approximately 220,200 underlying shares of ABBV. Below is a chart showing SBUX's trailing twelve month trading history, with the $52 strike highlighted in orange: AbbVie Inc ... | Below is a chart showing SBUX's trailing twelve month trading history, with the $52 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 34,203 contracts, representing approximately 3.4 million underlying shares or approximately 52.4% of ABBV's average daily trading volume over the past... | Below is a chart showing SBUX's trailing twelve month trading history, with the $52 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 34,203 contracts, representing approximately 3.4 million underlying shares or approximately 52.4% of ABBV's average daily trading volume over the past... | Below is a chart showing SBUX's trailing twelve month trading history, with the $52 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 34,203 contracts, representing approximately 3.4 million underlying shares or approximately 52.4% of ABBV's average daily trading volume over the past... |
25,402 | 2018-07-26 00:00:00 UTC | Notable ETF Inflow Detected - IUSG, ABBV, CRM, PYPL | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-iusg-abbv-crm-pypl-2018-07-26 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $151.3 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 80,100... | Among the largest underlying components of IUSG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Salesforce.com Inc (Symbol: CRM) is down about 0.6%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 3.4%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one ... | Among the largest underlying components of IUSG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Salesforce.com Inc (Symbol: CRM) is down about 0.6%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 3.4%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one ... | Among the largest underlying components of IUSG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Salesforce.com Inc (Symbol: CRM) is down about 0.6%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 3.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... | Among the largest underlying components of IUSG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Salesforce.com Inc (Symbol: CRM) is down about 0.6%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 3.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered ... |
25,403 | 2018-07-26 00:00:00 UTC | 5 Must-See Earnings Charts to End the Week | ABBV | https://www.nasdaq.com/articles/5-must-see-earnings-charts-end-week-2018-07-26 | null | null | Earnings season has picked up this week. There are over 800 companies expected to report, including many of the large S&P 500 companies.
While FAANG gets all the glory, a lot of investor favorites are also reporting earnings this week including the two largest Big Oil companies in the United States and several large ca... | AbbVie ABBV has a great track record of beating. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report BG Staffing Inc (BGSF): Free S... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report BG Staffing Inc (BGSF): Free Stock Analysis Report To read this article on Zack... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report BG Staffing Inc (BGSF): Free Stock Analysis Report To read this article on Zack... | AbbVie ABBV has a great track record of beating. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report BG Staffing Inc (BGSF): Free S... |
25,404 | 2018-07-26 00:00:00 UTC | Pre-Market Earnings Report for July 27, 2018 : XOM, CVX, MRK, ABBV, CL, PSX, AON, MCO, TWTR, IMO, WY, SYF | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-july-27-2018-xom-cvx-mrk-abbv-cl-psx-aon-mco-twtr-imo-wy-syf | null | null | The following companies are expected to report earnings prior to market open on 07/27/2018. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation ( XOM ) is reporting for the quarter ending June 30, 2018. The oil company's consensus earnings per share forecast from the 5 ana... | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 11.94 vs. an industry ratio of 16.20. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 11.94 vs. an industry ratio of 16.20. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 11.94 vs. an industry ratio of 16.20. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending June 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 11.94 vs. an industry ratio of 16.20. |
25,405 | 2018-07-25 00:00:00 UTC | AbbVie Secures FDA Approval for Endometriosis Drug Elagolix | ABBV | https://www.nasdaq.com/articles/abbvie-secures-fda-approval-for-endometriosis-drug-elagolix-2018-07-25 | null | null | AbbVie Inc . ABBV together with its partner Neurocrine Biosciences announced that the FDA has approved its pipeline candidate, elagolix, for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women.
The candidate to be marketed by the trade name of Orilissa is expec... | ABBV together with its partner Neurocrine Biosciences announced that the FDA has approved its pipeline candidate, elagolix, for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women. The FDA requested for a prolonged time frame to review additional information pr... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Vanda Pharmaceuticals Inc. (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc . ABBV together wi... | With Orilissa approved to treat pain associated with endometriosis, it can address a market with significant unmet need to bring in more sales for AbbVie. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stoc... | With Orilissa approved to treat pain associated with endometriosis, it can address a market with significant unmet need to bring in more sales for AbbVie. Notably, last September, the FDA accepted AbbVie's new drug application (NDA) for Orilissa and subsequently, granted priority review status in October. AbbVie Inc . |
25,406 | 2018-07-24 00:00:00 UTC | Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings? | ABBV | https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-abbvie-abbv-in-q2-earnings-2018-07-24 | null | null | We expect AbbVie Inc.ABBV to beat expectations when it reports second-quarter 2018 results on Jul 27, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 3.89%.
Shares of AbbVie have declined 7.6% compared with the industry 's decrease of 1.3% so far this year.
Let's ... | Factors to Consider AbbVie's flagship product, Humira, which is approved for several inflammatory indications, continues to witness strong demand trends despite launch of drugs with new mechanisms of action and competition from indirect biosimilars. AbbVie also submitted regulatory application in the United States and ... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Other Stocks That Warrant a Look Here are a couple of other health care stocks with the right combination of elements to surpass estimates this time around: Pfizer PFE is scheduled to release results on Jul 31. Click to get this f... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We expect AbbVie Inc.ABBV to beat expectat... | We expect AbbVie Inc.ABBV to beat expectations when it reports second-quarter 2018 results on Jul 27, before market open. Shares of AbbVie have declined 7.6% compared with the industry 's decrease of 1.3% so far this year. Factors to Consider AbbVie's flagship product, Humira, which is approved for several inflammatory... |
25,407 | 2018-07-24 00:00:00 UTC | Merck (MRK) Q2 Earnings Coming Up: What's in the Cards? | ABBV | https://www.nasdaq.com/articles/merck-mrk-q2-earnings-coming-up%3A-whats-in-the-cards-2018-07-24 | null | null | Merck & Co., Inc.MRK will report second-quarter 2018 results on Jul 27, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 6.06%.
Merck's performance has been pretty impressive, with the company exceeding earnings expectations in all the trailing four quarters. The a... | These have the right combination of elements to beat on earnings this time around: AbbVie, Inc. ABBV has an Earnings ESP of +0.15% and a Zacks Rank of 3. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock ... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. These have the right combination of elements ... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. These have the right combination of elements ... | These have the right combination of elements to beat on earnings this time around: AbbVie, Inc. ABBV has an Earnings ESP of +0.15% and a Zacks Rank of 3. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock ... |
25,408 | 2018-07-24 00:00:00 UTC | What to Expect When AbbVie Reports Q2 Earnings | ABBV | https://www.nasdaq.com/articles/what-expect-when-abbvie-reports-q2-earnings-2018-07-24 | null | null | AbbVie (NYSE: ABBV) knocked the ball out of the park when it reported its first-quarter earnings results in April. Revenue and earnings came in higher than expected thanks to strong momentum for new HIV drug Mavyret and solid growth for top-selling Humira.
The big drugmaker provides an update on its second-quarter perf... | But AbbVie won another key FDA approval for Venclexta early last month as a second-line treatment in combination with Roche 's Rituxan for patients with CLL or small lymphocytic lymphoma (SLL) with or without the 17p deletion. My view is that Humira, Imbruvica, Mavyret, and Venclexta, along with promising pipeline cand... | AbbVie (NYSE: ABBV) knocked the ball out of the park when it reported its first-quarter earnings results in April. Here's what you can expect from AbbVie's Q2 earnings announcement. The primary reason for this is that AbbVie benefited from the timing of shipments in the first quarter that won't be a factor this time ar... | Big bucks but moderating growth for Mavyret Mavyret was the star of the show when AbbVie reported its Q1 earnings results. My view is that Humira, Imbruvica, Mavyret, and Venclexta, along with promising pipeline candidates elagolix, risankizumab, and upadacitinib, will ultimately be "ghostbusters" for AbbVie. AbbVie (N... | Big bucks but moderating growth for Mavyret Mavyret was the star of the show when AbbVie reported its Q1 earnings results. AbbVie (NYSE: ABBV) knocked the ball out of the park when it reported its first-quarter earnings results in April. Here's what you can expect from AbbVie's Q2 earnings announcement. |
25,409 | 2018-07-24 00:00:00 UTC | What's in Store for Cardinal Health (CAH) in Q4 Earnings? | ABBV | https://www.nasdaq.com/articles/whats-in-store-for-cardinal-health-cah-in-q4-earnings-2018-07-24 | null | null | Cardinal Health, Inc 's CAH fourth-quarter fiscal 2018 results are scheduled for release on Aug 6, before the market opens. While results are likely to project impressive growth in the core Pharmaceutical segment, lackluster performance in the Cordis unit is likely to mar prospects.
In the last reported quarter, the co... | AbbVie Inc ABBV has an Earnings ESP of +0.15% and a Zacks Rank of 3. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To ... | Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc ABBV has an Ear... | Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc ABBV has an Ear... | AbbVie Inc ABBV has an Earnings ESP of +0.15% and a Zacks Rank of 3. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To ... |
25,410 | 2018-07-23 00:00:00 UTC | Healthcare ETFs to Buy on Solid Q2 Earnings Expectations | ABBV | https://www.nasdaq.com/articles/healthcare-etfs-buy-solid-q2-earnings-expectations-2018-07-23 | null | null | Healthcare has been the second-best performing sector in the three-month time period driven by its non-cyclical nature, which provides a defensive tilt to the portfolio in a turbulent market against a rising M&A and positive regulatory backdrop (read: 5 Safe and Sound ETF Strategies for 2H ).
A popular ETF like Health ... | The strength is likely to continue heading into the Q2 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ESP of +0.15%. Click to get thi... | The strength is likely to continue heading into the Q2 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Sto... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Report... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Report... |
25,411 | 2018-07-23 00:00:00 UTC | Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings? | ABBV | https://www.nasdaq.com/articles/is-a-beat-in-store-for-bristol-myers-bmy-in-q2-earnings-2018-07-23 | null | null | We expect Bristol-Myers Squibb CompanyBMY to beat expectations when it reports second-quarter 2018 results on Jul 26, before market open.
Bristol-Myers' shares have decreased 7.4% so far this year compared with the industry 's decline of 1.2%.
The company delivered positive earnings surprise in three of the last four q... | AbbVie ABBV is scheduled to release its results on Jul 27. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Horizon Pharma Public Limited Company (HZNP): Free Stock Analysis Report To... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Horizon Pharma Public Limited Company (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV is ... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Horizon Pharma Public Limited Company (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV is ... | AbbVie ABBV is scheduled to release its results on Jul 27. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Horizon Pharma Public Limited Company (HZNP): Free Stock Analysis Report To... |
25,412 | 2018-07-23 00:00:00 UTC | Better Buy: Gilead Sciences, Inc. vs. Celgene | ABBV | https://www.nasdaq.com/articles/better-buy-gilead-sciences-inc-vs-celgene-2018-07-23 | null | null | Gilead Sciences, Inc. (NASDAQ: GILD) and Celgene Corporation (NASDAQ: CELG) have both produced tremendous gains for long-term shareholders. Over a three-year period leading up to mid-2015, both of these stocks quadrupled their investors' money.
The past three years haven't been total disasters, but Gilead's underperfor... | The case for Gilead Sciences About a year ago, AbbVie Inc. (NYSE: ABBV) earned approval for an effective hepatitis C virus (HCV) treatment to compete with Gilead's and launched it at a price that caught the market leader off guard. With regards to HCV treatment prices, AbbVie and Gilead have been chasing each other to ... | The case for Gilead Sciences About a year ago, AbbVie Inc. (NYSE: ABBV) earned approval for an effective hepatitis C virus (HCV) treatment to compete with Gilead's and launched it at a price that caught the market leader off guard. With regards to HCV treatment prices, AbbVie and Gilead have been chasing each other to ... | The case for Gilead Sciences About a year ago, AbbVie Inc. (NYSE: ABBV) earned approval for an effective hepatitis C virus (HCV) treatment to compete with Gilead's and launched it at a price that caught the market leader off guard. With regards to HCV treatment prices, AbbVie and Gilead have been chasing each other to ... | With regards to HCV treatment prices, AbbVie and Gilead have been chasing each other to the bottom for a long time. The case for Gilead Sciences About a year ago, AbbVie Inc. (NYSE: ABBV) earned approval for an effective hepatitis C virus (HCV) treatment to compete with Gilead's and launched it at a price that caught t... |
25,413 | 2018-07-23 00:00:00 UTC | AbbVie's Stock Is a Bargain After Falling 8% Last Week | ABBV | https://www.nasdaq.com/articles/abbvies-stock-bargain-after-falling-8-last-week-2018-07-23 | null | null | Big pharma and blue-chip biotech stocks rarely lose 8% of their value in a single week, but that's exactly what happened to AbbVie (NYSE: ABBV) last week. The drugmaker's stock sank after FDA Commissioner Scott Gottlieb stated that he is working toward making it easier for knock-off biologic drugs called biosimilars to... | The drugmaker's stock sank after FDA Commissioner Scott Gottlieb stated that he is working toward making it easier for knock-off biologic drugs called biosimilars to enter the market, which could become a significant threat to AbbVie's top line. AbbVie's top-selling anti-inflammatory medicine, Humira, tends to make up ... | To ward off would-be copycats, AbbVie has built a massive patent portfolio covering nearly every aspect of how the drug is manufactured, and more recently, the biotech signed licensing agreements with the likes of Amgen (NASDAQ: AMGN) and Mylan (NASDAQ: MYL) to postpone the U.S. launch dates for their respective biosim... | The drugmaker's stock sank after FDA Commissioner Scott Gottlieb stated that he is working toward making it easier for knock-off biologic drugs called biosimilars to enter the market, which could become a significant threat to AbbVie's top line. To ward off would-be copycats, AbbVie has built a massive patent portfolio... | The drugmaker's stock sank after FDA Commissioner Scott Gottlieb stated that he is working toward making it easier for knock-off biologic drugs called biosimilars to enter the market, which could become a significant threat to AbbVie's top line. In fact, that's the main reason Amgen and Mylan agreed to sign these fairl... |
25,414 | 2018-07-23 00:00:00 UTC | Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings? | ABBV | https://www.nasdaq.com/articles/will-strong-hiv-sales-fuel-gilead-gild-in-q2-earnings-2018-07-23 | null | null | Biotech bigwig Gilead Sciences Inc.GILD develops drugs for the treatment of human immunodeficiency virus ("HIV"), liver diseases such as chronic hepatitis C virus ("HCV") infection and chronic hepatitis B virus ("HBV") infection, and cardiovascular, hematology/oncology and inflammation/respiratory diseases.
Gilead is a... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Merck's MRK Zepatier, among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gi... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been faci... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been faci... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR and Merck's MRK Zepatier, among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gi... |
25,415 | 2018-07-23 00:00:00 UTC | What’s Next for Pfizer Stock After Being Called Out by President Trump | ABBV | https://www.nasdaq.com/articles/whats-next-pfizer-stock-after-being-called-out-president-trump-2018-07-23 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Even though President Trump set his sights on Pfizer (NYSE: PFE ) after the company announced it would hike drug prices, PFE stock continued to trade on the higher end of its trading range. At a share price of just 5% percent below yearly highs, should inve... | AbbVie (NYSE: ABBV ) has a broad array of products in the pipeline. Competition will heat up in the years ahead as the FDA relaxes its review cycle and encourages generic suppliers to develop cheaper alternatives. But if the acquired company fails to produce a blockbuster drug, or worse, the clinical study flunks, then... | AbbVie (NYSE: ABBV ) has a broad array of products in the pipeline. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even though President Trump set his sights on Pfizer (NYSE: PFE ) after the company announced it would hike drug prices, PFE stock continued to trade on the higher end of its trading range.... | AbbVie (NYSE: ABBV ) has a broad array of products in the pipeline. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even though President Trump set his sights on Pfizer (NYSE: PFE ) after the company announced it would hike drug prices, PFE stock continued to trade on the higher end of its trading range.... | AbbVie (NYSE: ABBV ) has a broad array of products in the pipeline. President Trump tweeted his criticism on Pfizer's price hike on Jul. The big buyouts cost billions if it is a blockbuster deal. |
25,416 | 2018-07-20 00:00:00 UTC | AbbVie Becomes Oversold (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-becomes-oversold-abbv-2018-07-20 | null | null | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $86.76 per share. A bullish investor could look at ABBV's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and b... | The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $69.38 per share, with $125.86 as the 52 week high point - that compares with a last trade of $86.96. In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territ... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $86.76 per share. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $69.38 per share... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $86.76 per share. A bullish investor could look at ABBV's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and b... |
25,417 | 2018-07-20 00:00:00 UTC | 10 Cancer-Fighting Health Care Stocks to Buy | ABBV | https://www.nasdaq.com/articles/10-cancer-fighting-health-care-stocks-buy-2018-07-20 | null | null | Cancer. The mere mention of the word can drudge up discomfort, as most everyone knows it's second only to heart disease when it comes to claiming lives. Unlike heart disease, though, cancer is difficult to prevent and similarly difficult to fight.
The battle against the myriad forms of cancer, however, also is an oppor... | Marc Lichtenfeld, Chief Income Strategist for the Oxford Club, points out that "AbbVie's Imbruvica is being studied in more than 130 clinical trials," which includes some testing as a treatment for solid tumors. SEE ALSO: 10 Underappreciated Biotech Stocks to Buy Pharmaceutical giant AbbVie ( ABBV , $89.95) recently wa... | SEE ALSO: 10 Underappreciated Biotech Stocks to Buy Pharmaceutical giant AbbVie ( ABBV , $89.95) recently was forced to dish out some disappointing news. Marc Lichtenfeld, Chief Income Strategist for the Oxford Club, points out that "AbbVie's Imbruvica is being studied in more than 130 clinical trials," which includes ... | SEE ALSO: 10 Underappreciated Biotech Stocks to Buy Pharmaceutical giant AbbVie ( ABBV , $89.95) recently was forced to dish out some disappointing news. Marc Lichtenfeld, Chief Income Strategist for the Oxford Club, points out that "AbbVie's Imbruvica is being studied in more than 130 clinical trials," which includes ... | SEE ALSO: 10 Underappreciated Biotech Stocks to Buy Pharmaceutical giant AbbVie ( ABBV , $89.95) recently was forced to dish out some disappointing news. Marc Lichtenfeld, Chief Income Strategist for the Oxford Club, points out that "AbbVie's Imbruvica is being studied in more than 130 clinical trials," which includes ... |
25,418 | 2018-07-20 00:00:00 UTC | Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings? | ABBV | https://www.nasdaq.com/articles/will-hiv-sales-drive-gilead-gild-to-beat-in-q2-earnings-2018-07-20 | null | null | Biotech bigwig Gilead Sciences Inc.GILD is likely to beat expectations when it reports results for the second quarter on Jul 25, after the market closes .
Gilead has a decent track record, with the company's earnings beating estimates in three of the last four quaters. In the last reported quarter, the company's earnin... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Intercept Pharma... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and ... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Intercept Pharma... |
25,419 | 2018-07-19 00:00:00 UTC | 3 Big Stock Charts for Thursday: McDonald’s, AbbVie and Coca-Cola | ABBV | https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-mcdonalds-abbvie-and-coca-cola-2018-07-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It was touch and go for the market for the better part of Wednesday, though by the time the closing bell rang, stocks managed to (mostly) ended the day with a gain. The Nasdaq finished yesterday's action a hair in the red, while the S&P 500 edged 0.22% high... | To that end, Coca-Cola (NYSE: KO ), AbbVie (NYSE: ABBV ) and McDonald's (NYSE: MCD ) are lining up as Thursday's top prospects. AbbVie (ABBV) With just a quick glance AbbVie shares just look like they're bouncing around, without much direction. Click to Enlarge • AbbVie's best shot at a rebound was a couple of weeks ag... | To that end, Coca-Cola (NYSE: KO ), AbbVie (NYSE: ABBV ) and McDonald's (NYSE: MCD ) are lining up as Thursday's top prospects. AbbVie (ABBV) With just a quick glance AbbVie shares just look like they're bouncing around, without much direction. Click to Enlarge • AbbVie's best shot at a rebound was a couple of weeks ag... | More From InvestorPlace 5 Strong Earnings Stocks to Buy Post-Netflix Plunge 4 Underappreciated Stocks to Buy Before the Analysts Weigh In 5 Stocks That Could Double In the Next 5 Years 4 Solar Stocks to Buy, 4 to Avoid Compare Brokers The post 3 Big Stock Charts for Thursday: McDonald's, AbbVie and Coca-Cola appeared f... | To that end, Coca-Cola (NYSE: KO ), AbbVie (NYSE: ABBV ) and McDonald's (NYSE: MCD ) are lining up as Thursday's top prospects. AbbVie (ABBV) With just a quick glance AbbVie shares just look like they're bouncing around, without much direction. Click to Enlarge • AbbVie's best shot at a rebound was a couple of weeks ag... |
25,420 | 2018-07-19 00:00:00 UTC | Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2? | ABBV | https://www.nasdaq.com/articles/can-eli-lilly-lly-keep-the-earnings-streak-alive-in-q2-2018-07-19 | null | null | Eli Lilly and CompanyLLY will report second-quarter 2018 results on Jul 24, before market open. Last quarter, the company delivered a positive earnings surprise of 18.6%.
Lilly's shares have risen 6.6% this year so far while the industry recorded a decrease of 0.7%.
Lilly's earnings performance has been pretty impressi... | AbbVie, Inc. ABBV has an Earnings ESP of +0.11% and a Zacks Rank #3. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this artic... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc. ABBV has an Earnings ESP of ... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc. ABBV has an Earnings ESP of ... | AbbVie, Inc. ABBV has an Earnings ESP of +0.11% and a Zacks Rank #3. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this artic... |
25,421 | 2018-07-19 00:00:00 UTC | Why AbbVie Shares Are Sliding Today | ABBV | https://www.nasdaq.com/articles/why-abbvie-shares-are-sliding-today-2018-07-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie (NYSE: ABBV ) stock took a hit today following comments concerning biosimilars.
Source: Shutterstock
The comment that sent ABBV stock down today comes from research firm Citron Research. The following is the Tweet concerning AbbVie.
"$ABBV the next g... | TGT price $60 Gottlieb's comments for biosimilars and the removal of safe harbor is a DIRECT hit on Abbvie's abuse of Humira. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE: ABBV ) stock took a hit today following comments concerning biosimilars. Source: Shutterstock The comment that sent A... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE: ABBV ) stock took a hit today following comments concerning biosimilars. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Source: Shutterstock The comment tha... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE: ABBV ) stock took a hit today following comments concerning biosimilars. Source: Shutterstock The comment that sent ABBV stock down today comes from research firm Citron Research. The following is the Tweet concerning AbbVie. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE: ABBV ) stock took a hit today following comments concerning biosimilars. Source: Shutterstock The comment that sent ABBV stock down today comes from research firm Citron Research. The following is the Tweet concerning AbbVie. |
25,422 | 2018-07-19 00:00:00 UTC | Biogen (BIIB) to Report Q2 Earnings: What's in the Cards? | ABBV | https://www.nasdaq.com/articles/biogen-biib-to-report-q2-earnings%3A-whats-in-the-cards-2018-07-19 | null | null | Biogen Inc.BIIB will report second-quarter 2018results on Jul 24, before market open. Last quarter, the company delivered a positive earnings surprise of 2.02%.
Biogen's shares have risen 12.5% this year against the industry 's decline of 2.3% in the same time frame.
Biogen's earnings performance has been decent so far... | In March, Biogen and partner AbbVie announced the decision to withdraw Zinbryta from the markets due to growing safety concerns and limited commercial adoption of the drug due to its restrictive label. AbbVie, Inc. ABBV has an Earnings ESP of +0.11% and a Zacks Rank #3. Click to get this free report Roche Holding AG (R... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. In March, Biogen and partner AbbVie announced the d... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. In March, Biogen and partner AbbVie announced the d... | In March, Biogen and partner AbbVie announced the decision to withdraw Zinbryta from the markets due to growing safety concerns and limited commercial adoption of the drug due to its restrictive label. AbbVie, Inc. ABBV has an Earnings ESP of +0.11% and a Zacks Rank #3. Click to get this free report Roche Holding AG (R... |
25,423 | 2018-07-19 00:00:00 UTC | Notable Thursday Option Activity: ABBV, HSY, AVB | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-abbv-hsy-avb-2018-07-19 | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 78,614 contracts has been traded thus far today, a contract volume which is representative of approximately 7.9 million underlying shares (given that every ... | Especially high volume was seen for the $85 strike put option expiring July 20, 2018 , with 11,588 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc... | Below is a chart showing ABBV's trailing twelve month trading history, with the $85 strike highlighted in orange: Hershey Company (Symbol: HSY) options are showing a volume of 13,294 contracts thus far today. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today i... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 78,614 contracts has been traded thus far today, a contract volume which is representative of approximately 7.9 million underlying shares (given that every ... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 78,614 contracts has been traded thus far today, a contract volume which is representative of approximately 7.9 million underlying shares (given that every ... |
25,424 | 2018-07-17 00:00:00 UTC | J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales | ABBV | https://www.nasdaq.com/articles/jjs-jnj-q2-earnings-beat-on-higher-cancer-drug-sales-2018-07-17 | null | null | Johnson & JohnsonJNJ set the 2018 pharma earnings in motion by beating the Zacks Consensus Estimate on both counts in the second quarter of 2018. The drug and consumer products giant however narrowed its full year sales forecast, due to lower-than-previously expected currency tailwinds. The guidance cut pulled down sha... | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Re... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets... | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Re... |
25,425 | 2018-07-17 00:00:00 UTC | What's Behind Johnson & Johnson's Double-Digit Growth? | ABBV | https://www.nasdaq.com/articles/whats-behind-johnson-johnsons-double-digit-growth-2018-07-17 | null | null | Johnson & Johnson (NYSE: JNJ) is a healthcare giant that racks up tens of billions of dollars in revenue every quarter. Usually, it's tough to deliver double-digit growth when you get to be as big of a company as J&J. However, in the second quarter, its sales were 10.6% higher than one year ago.
What's behind this heal... | J&J shares the blood cancer drug Imbruvica with AbbVie (NYSE: ABBV) ; Imbruvica has also been a big beneficiary of an expanding addressable market. But sales really accelerated once the Food and Drug Administration approved its use earlier in treatment alongside other medications, including Celgene 's megablockbuster R... | J&J shares the blood cancer drug Imbruvica with AbbVie (NYSE: ABBV) ; Imbruvica has also been a big beneficiary of an expanding addressable market. That's a stiff headwind, but J&J was still able to deliver double-digit operational growth in the segment because of Stelara, Darzalex, Imbruvica, and Zytiga. Darzalex, a m... | J&J shares the blood cancer drug Imbruvica with AbbVie (NYSE: ABBV) ; Imbruvica has also been a big beneficiary of an expanding addressable market. Consumer-goods sales were flat and medical device revenue only grew 1.9% ex-currency, but after backing out currency and acquisitions, J&J's pharmaceutical sales jumped 11%... | J&J shares the blood cancer drug Imbruvica with AbbVie (NYSE: ABBV) ; Imbruvica has also been a big beneficiary of an expanding addressable market. In Q2, J&J's share of Imbruvica revenue was $620 million, up 34.2% year over year. The approval helped Zytiga's sales skyrocket nearly 60% year over year to $909 million la... |
25,426 | 2018-07-15 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 7/15/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-7152018-2018-07-15 | null | null | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
UNIVERSAL HEALTH SERVICES, INC. ( UHS... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Valide... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's hospitals provide a range of services, such as oncology... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's hospitals provide a range of services, such as oncology... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company operates in four segments: Cardiac and Vascular Group, Mi... |
25,427 | 2018-07-15 00:00:00 UTC | 3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018 | ABBV | https://www.nasdaq.com/articles/3-best-big-pharma-stocks-buy-2nd-half-2018-2018-07-15 | null | null | Few big pharma stocks excited investors in the first half of 2018. Sure, there were a few stocks that performed pretty well . Overall, though, the year has been at best mediocre for the stocks of major drugmakers. Could the rest of 2018 be a better picture? Maybe so.
Three big pharma stocks, in particular, could be set... | Here's why I think AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Gilead Sciences (NASDAQ: GILD) are the three best big pharma stocks to buy for the second half of 2018. AbbVie AbbVie stock was on a roll this year until the company's announcement in March of disappointing phase 2 study results for Rova-T in treatin... | Here's why I think AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Gilead Sciences (NASDAQ: GILD) are the three best big pharma stocks to buy for the second half of 2018. AbbVie AbbVie stock was on a roll this year until the company's announcement in March of disappointing phase 2 study results for Rova-T in treatin... | Here's why I think AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Gilead Sciences (NASDAQ: GILD) are the three best big pharma stocks to buy for the second half of 2018. AbbVie AbbVie stock was on a roll this year until the company's announcement in March of disappointing phase 2 study results for Rova-T in treatin... | Here's why I think AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Gilead Sciences (NASDAQ: GILD) are the three best big pharma stocks to buy for the second half of 2018. AbbVie AbbVie stock was on a roll this year until the company's announcement in March of disappointing phase 2 study results for Rova-T in treatin... |
25,428 | 2018-07-13 00:00:00 UTC | 5 Big Pharma Stocks Investors Love Right Now | ABBV | https://www.nasdaq.com/articles/5-big-pharma-stocks-investors-love-right-now-2018-07-13 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Solid clinical results for Biogen (NASDAQ: BIIB ) sent the stock up nearly 20% in a single day last week. That set the tone for a number of hot drug stock picks for July.
The bullish madness did not stop at Biogen last week. News of positive clinical data f... | Big Pharma Stocks Investors Love: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has an immense portfolio of drugs and many more in the pipeline. Humira is a core AbbVie product that accounts for 60% of its total net present value. CS concedes that AbbVie's patents are protected in the U.S. until 2023, but tha... | Big Pharma Stocks Investors Love: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has an immense portfolio of drugs and many more in the pipeline. Humira is a core AbbVie product that accounts for 60% of its total net present value. CS concedes that AbbVie's patents are protected in the U.S. until 2023, but tha... | Big Pharma Stocks Investors Love: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has an immense portfolio of drugs and many more in the pipeline. Humira is a core AbbVie product that accounts for 60% of its total net present value. CS concedes that AbbVie's patents are protected in the U.S. until 2023, but tha... | Big Pharma Stocks Investors Love: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has an immense portfolio of drugs and many more in the pipeline. Humira is a core AbbVie product that accounts for 60% of its total net present value. CS concedes that AbbVie's patents are protected in the U.S. until 2023, but tha... |
25,429 | 2018-07-13 00:00:00 UTC | Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings? | ABBV | https://www.nasdaq.com/articles/will-jjs-jnj-pharma-segment-strength-drive-q2-earnings-2018-07-13 | null | null | Johnson & JohnsonJNJ has one of the most diverse revenue streams in the industry within the pharmaceutical division, which accounts for almost half of its revenues. The company has several multi-million dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism; immunology, oncolog... | Please note that J&J markets Imbruvica in partnership with AbbVie ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this ar... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets Imbruvica in ... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets Imbruvica in ... | Please note that J&J markets Imbruvica in partnership with AbbVie ABBV . Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this ar... |
25,430 | 2018-07-13 00:00:00 UTC | 2 Overlooked Biotech Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/2-overlooked-biotech-stocks-buy-now-2018-07-13 | null | null | A staggering amount of money is flowing into new companies with promising new technologies, many of which will lead to innovative new drugs. There have been 32 biotech IPOs on the Nasdaq exchange in 2018, and dozens more have raised nine-figure sums privately.
The recent surge in biotech investment is terrific for the ... | AbbVie and Amgen aren't risky start-ups that can double your money overnight, but their operations churn out enough cash to snap up tomorrow's blockbusters today. AbbVie Inc.: Partnerships big and small The world's top-selling drug, Humira, generates some tremendous cash flows for AbbVie, which it has deftly invested i... | AbbVie and Amgen aren't risky start-ups that can double your money overnight, but their operations churn out enough cash to snap up tomorrow's blockbusters today. AbbVie Inc.: Partnerships big and small The world's top-selling drug, Humira, generates some tremendous cash flows for AbbVie, which it has deftly invested i... | AbbVie Inc.: Partnerships big and small The world's top-selling drug, Humira, generates some tremendous cash flows for AbbVie, which it has deftly invested into new drug candidates at various stages of development. AbbVie and Amgen aren't risky start-ups that can double your money overnight, but their operations churn ... | AbbVie and Amgen aren't risky start-ups that can double your money overnight, but their operations churn out enough cash to snap up tomorrow's blockbusters today. AbbVie Inc.: Partnerships big and small The world's top-selling drug, Humira, generates some tremendous cash flows for AbbVie, which it has deftly invested i... |
25,431 | 2018-07-12 00:00:00 UTC | Keep Your Eyes on Healthcare's Odd Couple: AbbVie and Alphabet | ABBV | https://www.nasdaq.com/articles/keep-your-eyes-healthcares-odd-couple-abbvie-and-alphabet-2018-07-12 | null | null | One small step for two companies, one giant leap for mankind? That might be what we see in retrospect years from now.
AbbVie (NYSE: ABBV) and Calico, a life sciences company funded by Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) , recently announced a three-year extension of their collaboration to develop therapies for age-... | AbbVie (NYSE: ABBV) and Calico, a life sciences company funded by Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) , recently announced a three-year extension of their collaboration to develop therapies for age-related diseases, including cancer and neurodegenerative disorders. There's no guarantee that anything significant wil... | AbbVie (NYSE: ABBV) and Calico, a life sciences company funded by Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) , recently announced a three-year extension of their collaboration to develop therapies for age-related diseases, including cancer and neurodegenerative disorders. There's no guarantee that anything significant wil... | AbbVie (NYSE: ABBV) and Calico, a life sciences company funded by Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) , recently announced a three-year extension of their collaboration to develop therapies for age-related diseases, including cancer and neurodegenerative disorders. Nearly one year after its founding, Calico partner... | Neither AbbVie nor Alphabet depends on Calico's success in its efforts. AbbVie (NYSE: ABBV) and Calico, a life sciences company funded by Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) , recently announced a three-year extension of their collaboration to develop therapies for age-related diseases, including cancer and neurode... |
25,432 | 2018-07-11 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018 | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-ex-dividend-date-scheduled-july-12-2018-2018-07-11 | null | null | AbbVie Inc. ( ABBV ) will begin trading ex-dividend on July 12, 2018. A cash dividend payment of $0.96 per share is scheduled to be paid on August 15, 2018. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 50% increase over prior dividend payme... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABBV's forecasted earnings growth in 2018 as 39.22%, compared to an industry average of 7.4%. For more information on the declaration, record and payment dates, visit the ABBV Divi... | The following ETF(s) have ABBV as a top-10 holding: Inspire 100 ETF ( BIBL ) Vanguard Health Care ETF ( VHT ) iShares U.S. Healthcare ETF ( IYH ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULG ). The views and opinions expressed herein are the views and opinions of the author... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. The following ETF(s) have ABBV as a top-10 holding: Inspire 100 ETF ( BIBL ) Vanguard Health Care ETF ( VHT )... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. ABBV's current earnings per share, an indicator of a company's profitability, is $3.97. AbbVie Inc. ( ABBV ) will begin trading ex-dividend on July 12, 2018. |
25,433 | 2018-07-10 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, Abbott Laboratories and Patterson Companies | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder-abbvie-abbott-laboratories-and-patterson-companies-2018-07-10 | null | null | Looking at the universe of stocks we cover at Dividend Channel , on 7/12/18, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Patterson Companies Inc (Symbol: PDCO) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $0.96 on 8/15/18, Abbott... | As a percentage of ABBV's recent stock price of $97.23, this dividend works out to approximately 0.99%, so look for shares of AbbVie Inc to trade 0.99% lower - all else being equal - when ABBV shares open for trading on 7/12/18. If they do continue, the current estimated yields on annualized basis would be 3.95% for Ab... | Looking at the universe of stocks we cover at Dividend Channel , on 7/12/18, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Patterson Companies Inc (Symbol: PDCO) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $0.96 on 8/15/18, Abbott... | Looking at the universe of stocks we cover at Dividend Channel , on 7/12/18, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Patterson Companies Inc (Symbol: PDCO) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $0.96 on 8/15/18, Abbott... | Looking at the universe of stocks we cover at Dividend Channel , on 7/12/18, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Patterson Companies Inc (Symbol: PDCO) will all trade ex-dividend for their respective upcoming dividends. As a percentage of ABBV's recent stock price of $97.23, this dividend ... |
25,434 | 2018-07-10 00:00:00 UTC | The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-apache-continental-resources-kmg-chemicals-zagg-and | null | null | For Immediate Release
Chicago, IL - July 10, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Apache Corp. APA , Continental... | Stocks recently featured in the blog include Apache Corp. APA , Continental Resources, Inc. CLR , KMG Chemicals, Inc. KMG , ZAGG Inc ZAGG and AbbVie Inc. ABBV . AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analys... | Stocks recently featured in the blog include Apache Corp. APA , Continental Resources, Inc. CLR , KMG Chemicals, Inc. KMG , ZAGG Inc ZAGG and AbbVie Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report KMG Chemicals, Inc. (KMG): Free Stock Analysis Report ZAGG Inc (ZAGG): Free Stock ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report KMG Chemicals, Inc. (KMG): Free Stock Analysis Report ZAGG Inc (ZAGG): Free Stock Analysis Report Apache Corporation (APA): Free Stock Analysis Report Continental Resources, Inc. (CLR): Free Stock Analysis Report To read this article on Zacks.... | Stocks recently featured in the blog include Apache Corp. APA , Continental Resources, Inc. CLR , KMG Chemicals, Inc. KMG , ZAGG Inc ZAGG and AbbVie Inc. ABBV . AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analys... |
25,435 | 2018-07-09 00:00:00 UTC | Better Buy: Eli Lilly and Company vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-buy-eli-lilly-and-company-vs-abbvie-2018-07-09 | null | null | Shares of AbbVie (NYSE: ABBV) started out the year with a bang, while around the same time, Eli Lilly 's (NYSE: LLY) stock price began to slide. Fast-forward to the present, however, and the former laggard is in the lead, albeit with a meager 2% gain.
Is a less expensive AbbVie the better buy now, or will new drug laun... | On the way down Mavyret and Imbruvica are growing fast, but AbbVie still depends on it's flagship rheumatoid arthritis therapy, Humira, for the lion's share of its growth, and 59% of its total revenue. Shares of AbbVie (NYSE: ABBV) started out the year with a bang, while around the same time, Eli Lilly 's (NYSE: LLY) s... | Is a less expensive AbbVie the better buy now, or will new drug launches give Eli Lilly the edge? AbbVie shares offer an attractive 4% yield at recent prices, and earlier this year, its board approved a $10 billion stock repurchase program. Shares of AbbVie (NYSE: ABBV) started out the year with a bang, while around th... | Shares of AbbVie (NYSE: ABBV) started out the year with a bang, while around the same time, Eli Lilly 's (NYSE: LLY) stock price began to slide. AbbVie shares offer an attractive 4% yield at recent prices, and earlier this year, its board approved a $10 billion stock repurchase program. Is a less expensive AbbVie the b... | Is a less expensive AbbVie the better buy now, or will new drug launches give Eli Lilly the edge? Shares of AbbVie (NYSE: ABBV) started out the year with a bang, while around the same time, Eli Lilly 's (NYSE: LLY) stock price began to slide. AbbVie shares offer an attractive 4% yield at recent prices, and earlier this... |
25,436 | 2018-07-09 00:00:00 UTC | Celebrate Trump's 2nd Year in Office With These 5 Winners | ABBV | https://www.nasdaq.com/articles/celebrate-trumps-2nd-year-office-these-5-winners-2018-07-09 | null | null | It's time to celebrate President Trump's second year in office. After all, in two out of every three times, the second years of presidential terms have favored stock investors,.
Wall Street, by the way, has shown enough confidence even as concerns about trade war loom large. As a matter of fact, solid job additions las... | AbbVie Inc.ABBV discovers, develops, manufactures, and sells pharmaceutical products worldwide. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report KMG Chemicals, Inc. (KMG): Free Stock Analysi... | Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report KMG Chemicals, Inc. (KMG): Free Stock Analysis Report ZAGG Inc (ZAGG): Free Stock Analysis Report Apache Corporation (APA): Free Stock Analys... | Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report KMG Chemicals, Inc. (KMG): Free Stock Analysis Report ZAGG Inc (ZAGG): Free Stock Analysis Report Apache Corporation (APA): Free Stock Analys... | AbbVie Inc.ABBV discovers, develops, manufactures, and sells pharmaceutical products worldwide. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report KMG Chemicals, Inc. (KMG): Free Stock Analysi... |
25,437 | 2018-07-09 00:00:00 UTC | SPYG, V, BA, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/spyg-v-ba-abbv-etf-inflow-alert-2018-07-09 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $132.4 million dollar inflow -- that's a 4.9% increase week over week in outstanding units (from 75,15... | Among the largest underlying components of SPYG, in trading today Visa Inc (Symbol: V) is up about 0.7%, Boeing Co. (Symbol: BA) is up about 1.7%, and AbbVie Inc (Symbol: ABBV) is higher by about 1.3%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance o... | Among the largest underlying components of SPYG, in trading today Visa Inc (Symbol: V) is up about 0.7%, Boeing Co. (Symbol: BA) is up about 1.7%, and AbbVie Inc (Symbol: ABBV) is higher by about 1.3%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance o... | Among the largest underlying components of SPYG, in trading today Visa Inc (Symbol: V) is up about 0.7%, Boeing Co. (Symbol: BA) is up about 1.7%, and AbbVie Inc (Symbol: ABBV) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one sta... | Among the largest underlying components of SPYG, in trading today Visa Inc (Symbol: V) is up about 0.7%, Boeing Co. (Symbol: BA) is up about 1.7%, and AbbVie Inc (Symbol: ABBV) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one sta... |
25,438 | 2018-07-06 00:00:00 UTC | 3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July | ABBV | https://www.nasdaq.com/articles/3-buy-rated-large-cap-pharma-stocks-boost-health-july-2018-07-06 | null | null | The large cap pharmaceuticals sector comprising some of the biggest drugmakers of the world was off to a strong start in 2018. However, the sector took a backseat due to reasons like U.S. market instability and a few negative updates on the pipeline as well as regulatory front. Also, some older drugs of these companies... | AbbVie Inc.ABBV AbbVie's key arthritis drug, Humira, is performing well on strong demand trends despite new competition. Mavyret for hepatitis C virus has become a major growth driver for AbbVie in a short span within the market. Moreover, AbbVie boasts an impressive late-stage pipeline with label expansions for both n... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV AbbVie's key arthritis drug, Hum... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV AbbVie's key arthritis drug, Hum... | AbbVie Inc.ABBV AbbVie's key arthritis drug, Humira, is performing well on strong demand trends despite new competition. Mavyret for hepatitis C virus has become a major growth driver for AbbVie in a short span within the market. Moreover, AbbVie boasts an impressive late-stage pipeline with label expansions for both n... |
25,439 | 2018-07-06 00:00:00 UTC | 3 Top Biotech Stocks to Buy in July | ABBV | https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-july-2018-07-06 | null | null | Biotechnology stocks can pop or drop because of clinical trial successes or failures, and that makes investing in biotech stocks riskier than investing in other industries. Nevertheless, the rewards for those biotech companies that successfully innovate new therapies can be significant, and that makes stocks like Regen... | Nevertheless, the rewards for those biotech companies that successfully innovate new therapies can be significant, and that makes stocks like Regenxbio (NASDAQ: RGNX) , Regeneron Pharmaceuticals (NASDAQ: REGN) , and AbbVie (NYSE: ABBV) worth considering. Keith Speights (AbbVie): There are few stocks on the market that ... | Nevertheless, the rewards for those biotech companies that successfully innovate new therapies can be significant, and that makes stocks like Regenxbio (NASDAQ: RGNX) , Regeneron Pharmaceuticals (NASDAQ: REGN) , and AbbVie (NYSE: ABBV) worth considering. Keith Speights (AbbVie): There are few stocks on the market that ... | Nevertheless, the rewards for those biotech companies that successfully innovate new therapies can be significant, and that makes stocks like Regenxbio (NASDAQ: RGNX) , Regeneron Pharmaceuticals (NASDAQ: REGN) , and AbbVie (NYSE: ABBV) worth considering. Keith Speights (AbbVie): There are few stocks on the market that ... | Keith Speights (AbbVie): There are few stocks on the market that can appeal to every kind of investor, but I think one big biotech stock just might: AbbVie. What's not to like about AbbVie? Nevertheless, the rewards for those biotech companies that successfully innovate new therapies can be significant, and that makes ... |
25,440 | 2018-07-06 00:00:00 UTC | Bristol-Myers' Sprycel Gets EC Approval for Label Expansion | ABBV | https://www.nasdaq.com/articles/bristol-myers-sprycel-gets-ec-approval-for-label-expansion-2018-07-06 | null | null | Bristol-Myers Squibb Company BMY announced that the European Commission (EC) has approved the label expansion of oncology drug Sprycel.
Consequently, the drug is now approved for the treatment of children and adolescents aged one year to 18 years with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML... | Bristol-Myers is co-developing Empliciti with AbbVie ABBV . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this ar... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers is co-developin... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers is co-developin... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers is co-developin... |
25,441 | 2018-07-05 00:00:00 UTC | Here's Why AbbVie Stock is Good for Your Portfolio's Health | ABBV | https://www.nasdaq.com/articles/heres-why-abbvie-stock-is-good-for-your-portfolios-health-2018-07-05 | null | null | AbbVie, Inc.ABBV shares have outperformed the large-cap pharma industry in the past three months. The stock has returned 1.5% in that timeframe against the industry 's decline of 1.1%.
It is one of the reputed names in the pharmaceutical sector. AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories ABT d... | AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division Here are six reasons to invest in the stock. Price-to-Earnings Forward Twelve Months (F12M) chart Key DrugHumira Going Strong: AbbVie's flagship product Humira is approved for several inflammatory indications l... | Price-to-Earnings Forward Twelve Months (F12M) chart Key DrugHumira Going Strong: AbbVie's flagship product Humira is approved for several inflammatory indications like rheumatoid arthritis. AbbVie is also studying another cancer drug Venclyxto/Venclexta to expand the label to address the broader relapsed/refractory ch... | Mavyret Performs Beyond Expectations: AbbVie's eight-week, pan-genotypic, ribavirin-free, once-daily hepatitis C (HCV) treatment, Mavyret, gained approval in the United States, EU, Canada and Japan in 2017. Conclusion AbbVie faces its share of challenges in the form of slower sales of HCV drugs, potential biosimilar co... | AbbVie, Inc.ABBV shares have outperformed the large-cap pharma industry in the past three months. AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division Here are six reasons to invest in the stock. Favorable Rank & Earnings Surprise Record: AbbVie has a Zacks Rank ... |
25,442 | 2018-07-05 00:00:00 UTC | If You Like Dividends, You Should Love These 3 Stocks | ABBV | https://www.nasdaq.com/articles/if-you-dividends-you-should-love-these-3-stocks-2018-07-05 | null | null | If you don't like dividends, you should. Between 1960 and 2017, a whopping 82% of the total return of the S&P 500 index came from the compound growth of reinvesting dividends.
And if you do like dividends, you should especially love three stocks: AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Welltower (NYSE: WELL) . Here'... | And if you do like dividends, you should especially love three stocks: AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Welltower (NYSE: WELL) . AbbVie AbbVie's dividend currently yields 4.14%. Since 2013, AbbVie has increased its dividend by 140%. | And if you do like dividends, you should especially love three stocks: AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Welltower (NYSE: WELL) . AbbVie AbbVie's dividend currently yields 4.14%. Since 2013, AbbVie has increased its dividend by 140%. | And if you do like dividends, you should especially love three stocks: AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Welltower (NYSE: WELL) . AbbVie AbbVie's dividend currently yields 4.14%. Since 2013, AbbVie has increased its dividend by 140%. | AbbVie AbbVie's dividend currently yields 4.14%. And if you do like dividends, you should especially love three stocks: AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Welltower (NYSE: WELL) . Since 2013, AbbVie has increased its dividend by 140%. |
25,443 | 2018-07-03 00:00:00 UTC | 5 Great Dividend Growth Stocks to Counter Volatility | ABBV | https://www.nasdaq.com/articles/5-great-dividend-growth-stocks-counter-volatility-2018-07-03 | null | null | Volatility and uncertainty in the stock market has raised the appeal for dividend growth stocks. A history of dividend growth year over year leads to a healthy portfolio with a greater scope of capital appreciation as opposed to simple dividend paying stocks or those with high yields.
Why Dividend Growth?
Stocks that h... | It has a Zacks Rank #2 and Growth Score of A. Illinois-based AbbVie Inc. ABBV is a global research-based biopharmaceutical company, which discovers, develops, manufactures and sells pharmaceutical products worldwide. Click to get this free report Matson, Inc. (MATX): Free Stock Analysis Report AbbVie Inc. (ABBV): Free ... | Click to get this free report Matson, Inc. (MATX): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report The Progressive Corporation (PGR): Free Stock Analysis Report Brinker International, Inc. (EAT): Free Stock Analysis Report Vishay Intertechnology, Inc. (VSH): Free Stock Analysis Report To read ... | Click to get this free report Matson, Inc. (MATX): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report The Progressive Corporation (PGR): Free Stock Analysis Report Brinker International, Inc. (EAT): Free Stock Analysis Report Vishay Intertechnology, Inc. (VSH): Free Stock Analysis Report To read ... | It has a Zacks Rank #2 and Growth Score of A. Illinois-based AbbVie Inc. ABBV is a global research-based biopharmaceutical company, which discovers, develops, manufactures and sells pharmaceutical products worldwide. Click to get this free report Matson, Inc. (MATX): Free Stock Analysis Report AbbVie Inc. (ABBV): Free ... |
25,444 | 2018-07-03 00:00:00 UTC | AstraZeneca's Two New Cancer Drugs Get Approval in Japan | ABBV | https://www.nasdaq.com/articles/astrazenecas-two-new-cancer-drugs-get-approval-in-japan-2018-07-03 | null | null | AstraZenecaAZN announced that the Japanese regulatory authorities have granted approval to its PARP inhibitor, Lynparza tablets for the treatment of patients with unresectable or recurrent BRCA-mutated metastatic breast cancer in patients who have received prior chemotherapy. With this approval, Lynparza becomes the fi... | Better-ranked large-cap pharma stocks include Pfizer, Inc. PFE and AbbVie, Inc. ABBV both with a Zacks Rank #2 (Buy). AbbVie's stock has rallied 28.5% in the past year. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): ... | Better-ranked large-cap pharma stocks include Pfizer, Inc. PFE and AbbVie, Inc. ABBV both with a Zacks Rank #2 (Buy). Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free... | Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked large-cap pharma stocks include Pfi... | Better-ranked large-cap pharma stocks include Pfizer, Inc. PFE and AbbVie, Inc. ABBV both with a Zacks Rank #2 (Buy). AbbVie's stock has rallied 28.5% in the past year. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): ... |
25,445 | 2018-07-03 00:00:00 UTC | Is Pfizer's Price Hike an Effect of Drug Policy on Sector? | ABBV | https://www.nasdaq.com/articles/is-pfizers-price-hike-an-effect-of-drug-policy-on-sector-2018-07-03 | null | null | Pfizer, Inc.PFE is reportedly raising prices of almost 100 drugs, effective July 1. This is the second time that the drug giant has raised the prices of its drugs this year. The scrutiny of drug prices has increased since Trump assumed office. However, with a softer drug pricing policy formed last month, we expect othe... | Along with Pfizer, stock prices of several other large cap pharma companies moved north on Jul 2 including Johnson & Johnson JNJ , Eli Lilly and Company LLY and AbbVie Inc. ABBV . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson ... | Along with Pfizer, stock prices of several other large cap pharma companies moved north on Jul 2 including Johnson & Johnson JNJ , Eli Lilly and Company LLY and AbbVie Inc. ABBV . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson ... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Along with Pfizer, stock prices of several ... | Along with Pfizer, stock prices of several other large cap pharma companies moved north on Jul 2 including Johnson & Johnson JNJ , Eli Lilly and Company LLY and AbbVie Inc. ABBV . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson ... |
25,446 | 2018-07-03 00:00:00 UTC | 3 Reasons BeiGene Needs to Be on Your Radar | ABBV | https://www.nasdaq.com/articles/3-reasons-beigene-needs-be-your-radar-2018-07-03 | null | null | You've likely heard quite a bit about the massive opportunity for immuno-oncology (IO) in the U.S. and in Europe.
These are the drugs that train the body's immune system to seek and destroy cancerous cells and tumors. We globally spent $133 billion on the fight against cancer last year, and oncologists really like the ... | We've seen nearly all of big pharma -- including Roche , Bristol-Myers Squibb , and AbbVie (NYSE: ABBV) -- dedicating billions of dollars to develop the next wave of IO drugs. *Stock Advisor returns as of June 4, 2018 Simon Erickson owns shares of AbbVie, BeiGene, and Celgene. As part of those changes, China will now r... | We've seen nearly all of big pharma -- including Roche , Bristol-Myers Squibb , and AbbVie (NYSE: ABBV) -- dedicating billions of dollars to develop the next wave of IO drugs. *Stock Advisor returns as of June 4, 2018 Simon Erickson owns shares of AbbVie, BeiGene, and Celgene. Founded on the premise of becoming "the Ge... | We've seen nearly all of big pharma -- including Roche , Bristol-Myers Squibb , and AbbVie (NYSE: ABBV) -- dedicating billions of dollars to develop the next wave of IO drugs. *Stock Advisor returns as of June 4, 2018 Simon Erickson owns shares of AbbVie, BeiGene, and Celgene. As part of those changes, China will now r... | We've seen nearly all of big pharma -- including Roche , Bristol-Myers Squibb , and AbbVie (NYSE: ABBV) -- dedicating billions of dollars to develop the next wave of IO drugs. *Stock Advisor returns as of June 4, 2018 Simon Erickson owns shares of AbbVie, BeiGene, and Celgene. BeiGene has access to more than twice the ... |
25,447 | 2018-07-03 00:00:00 UTC | The 5 Biggest Blockbuster Drugs of 2024, and the Companies Poised to Profit From Them | ABBV | https://www.nasdaq.com/articles/5-biggest-blockbuster-drugs-2024-and-companies-poised-profit-them-2018-07-03 | null | null | Predicting the future is easy. Getting the prediction right is another thing altogether.
However, it's possible to predict with at least some degree of confidence which drugs are likely to be the biggest winners, if you don't go too far out into the future. Market research firm EvaluatePharma has done just that with it... | Here are the five biggest blockbusters of the future -- and the five companies that are poised to profit from these drugs: AbbVie (NYSE: ABBV) , Merck (NYSE: MRK) , Celgene (NASDAQ: CELG) , Bristol-Myers Squibb (NYSE: BMY) , and Pfizer (NYSE: PFE) . Humira Six years from now will look like last year in one respect: Abb... | Here are the five biggest blockbusters of the future -- and the five companies that are poised to profit from these drugs: AbbVie (NYSE: ABBV) , Merck (NYSE: MRK) , Celgene (NASDAQ: CELG) , Bristol-Myers Squibb (NYSE: BMY) , and Pfizer (NYSE: PFE) . 1 in 2017 with sales of $18.9 billion (including revenue made by AbbVi... | Here are the five biggest blockbusters of the future -- and the five companies that are poised to profit from these drugs: AbbVie (NYSE: ABBV) , Merck (NYSE: MRK) , Celgene (NASDAQ: CELG) , Bristol-Myers Squibb (NYSE: BMY) , and Pfizer (NYSE: PFE) . Humira Six years from now will look like last year in one respect: Abb... | Humira Six years from now will look like last year in one respect: AbbVie's Humira will still probably be the best-selling drug in the world. Here are the five biggest blockbusters of the future -- and the five companies that are poised to profit from these drugs: AbbVie (NYSE: ABBV) , Merck (NYSE: MRK) , Celgene (NASD... |
25,448 | 2018-07-02 00:00:00 UTC | Vertex's Shares Rally as a Rival's CF Candidate Disappoints | ABBV | https://www.nasdaq.com/articles/vertexs-shares-rally-as-a-rivals-cf-candidate-disappoints-2018-07-02 | null | null | Vertex Pharmaceuticals Incorporated 's VRTX shares rallied more than 15% on Jun 29, following the announcement of lower-than-expected top-line results from Galapagos NV's GLPG phase II study on cystic fibrosis ("CF") candidate, GLPG2737.
Galapagos is evaluating the candidate on top of Vertex's CF drug, Orkambi (lumacaf... | The CF studies are being conducted in partnership with AbbVie ABBV . However, AbbVie has opted not to proceed with the development of previously contemplated second triple combination therapy comprising GLPG3067, GLPG2222 and GLPG2737. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. The C... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. The C... | The CF studies are being conducted in partnership with AbbVie ABBV . However, AbbVie has opted not to proceed with the development of previously contemplated second triple combination therapy comprising GLPG3067, GLPG2222 and GLPG2737. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex ... |
25,449 | 2018-07-02 00:00:00 UTC | Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion | ABBV | https://www.nasdaq.com/articles/gileads-gild-car-t-therapy-gets-positive-chmp-opinion-2018-07-02 | null | null | Gilead Sciences, Inc . GILD announced that European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ("CHMP") has issued a positive opinion on the company's Marketing Authorization Application ("MAA") for CAR T therapy, axicabtagene ciloleucel, as a treatment for adult patients with relapsed or r... | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Mayret, and Merck's MRK Zepatier, among others. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gil... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa ... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclusa ... | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Mayret, and Merck's MRK Zepatier, among others. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gil... |
25,450 | 2018-07-02 00:00:00 UTC | Health Care Sector Update for 07/02/2018: ABBV,PRGO,TEVA,NVS,ADMP,MRK,AZN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-07022018-abbvprgotevanvsadmpmrkazn-2018-07-02-0 | null | null | Top Health Care Stocks
JNJ -0.29%
PFE -0.58%
ABT flat
MRK flat
AMGN -0.53%
Health care stocks were trading lower Monday morning.
Among health care stocks likely to move on news:
- AbbVie ( ABBV ), together with a partner company, has been ordered by a US district court judge to pay $448 million after using sham litigat... | Among health care stocks likely to move on news: - AbbVie ( ABBV ), together with a partner company, has been ordered by a US district court judge to pay $448 million after using sham litigation to illegally keep generic versions of AbbVie's AndroGel testosterone replacement drug from reaching the market. In other sect... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Among health care stocks likely to move on news: - AbbVie ( ABBV ), together with a partner company, has been ordered by a US district court judge to pay $448 million after using sham li... | Among health care stocks likely to move on news: - AbbVie ( ABBV ), together with a partner company, has been ordered by a US district court judge to pay $448 million after using sham litigation to illegally keep generic versions of AbbVie's AndroGel testosterone replacement drug from reaching the market. In other sect... | Among health care stocks likely to move on news: - AbbVie ( ABBV ), together with a partner company, has been ordered by a US district court judge to pay $448 million after using sham litigation to illegally keep generic versions of AbbVie's AndroGel testosterone replacement drug from reaching the market. Top Health Ca... |
25,451 | 2018-07-02 00:00:00 UTC | Health Care Sector Update for 07/02/2018: SNNA,MRNS,ABBV,PRGO,TEVA,NVS,ADMP | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-07022018-snnamrnsabbvprgotevanvsadmp-2018-07-02 | null | null | Top Health Care Stocks
JNJ +0.17%
PFE +0.06%
ABT -0.03%
MRK -0.49%
AMGN +0.17%
Health care stocks turned mixed this afternoon, including a nearly 0.2% drop for the NYSE Health Care Index. Shares of health care companies in the S&P 500, meanwhile, were up more than 0.2% and the Nasdaq Biotechnology index jumped out to a... | - AbbVie ( ABBV ) was narrowly lower this afternoon, Monday swinging between small gains and losses despite the drugmaker - together with a partner company - late Friday being ordered by a U.S. district court judge to pay $448 million to Teva Pharmaceuticals ( TEVA ) and Perrigo ( PRGO ) after using sham litigation to ... | - AbbVie ( ABBV ) was narrowly lower this afternoon, Monday swinging between small gains and losses despite the drugmaker - together with a partner company - late Friday being ordered by a U.S. district court judge to pay $448 million to Teva Pharmaceuticals ( TEVA ) and Perrigo ( PRGO ) after using sham litigation to ... | - AbbVie ( ABBV ) was narrowly lower this afternoon, Monday swinging between small gains and losses despite the drugmaker - together with a partner company - late Friday being ordered by a U.S. district court judge to pay $448 million to Teva Pharmaceuticals ( TEVA ) and Perrigo ( PRGO ) after using sham litigation to ... | - AbbVie ( ABBV ) was narrowly lower this afternoon, Monday swinging between small gains and losses despite the drugmaker - together with a partner company - late Friday being ordered by a U.S. district court judge to pay $448 million to Teva Pharmaceuticals ( TEVA ) and Perrigo ( PRGO ) after using sham litigation to ... |
25,452 | 2018-07-01 00:00:00 UTC | Pharma's 2 Biggest Setbacks in 2018 | ABBV | https://www.nasdaq.com/articles/pharmas-2-biggest-setbacks-2018-2018-07-01 | null | null | Developing new drugs is wildly expensive. Since 2007, for instance, the average cost of bringing a novel drug to market (a new molecular entity) has hovered around a jaw-dropping $3.9 billion, according to EvaluateGroup. When all drugs are thrown into the mix, however, this figure balloons to an unreal $5.5 billion.
Th... | With this theme in mind, here is a look at how AbbVie (NYSE: ABBV) and Celgene Corporation (NASDAQ: CELG) made the two most costly mistakes halfway through 2018 and why investors in these two elite biopharmas shouldn't necessarily panic over these blunders. AbbVie's top line is still forecast to rise at a healthy 4% co... | After posting dismal midstage trial results for third-line small-cell lung cancer last March, AbbVie revealed at the recent American Society for Clinical Oncology meeting that Rova-T's ongoing trials are showing little sign of efficacy, and poor side-effect profiles to boot. Over the course of Jan. 1, 2017, to the day ... | AbbVie's Rova-T In June 2016, AbbVie doled out $5.8 billion to acquire Stemcentrx for its cancer stem-cell therapy called Rova-T (rovalpituzumab tesirine) as a possible game-changing treatment for small-cell lung cancer. With this theme in mind, here is a look at how AbbVie (NYSE: ABBV) and Celgene Corporation (NASDAQ:... | With this theme in mind, here is a look at how AbbVie (NYSE: ABBV) and Celgene Corporation (NASDAQ: CELG) made the two most costly mistakes halfway through 2018 and why investors in these two elite biopharmas shouldn't necessarily panic over these blunders. AbbVie's Rova-T In June 2016, AbbVie doled out $5.8 billion to... |
25,453 | 2018-06-29 00:00:00 UTC | Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today | ABBV | https://www.nasdaq.com/articles/why-vertex-pharmaceuticals-incorporated-stock-surged-14-today-2018-06-29 | null | null | What happened
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) were trading 14% higher as of 11 a.m. EDT on Friday. The nice jump for the biotech stock came after Galapagos N.V. (NASDAQ: GLPG) announced disappointing results Thursday evening from a phase 2 clinical study evaluating C2 corrector GLPG2737 in ... | Now what Vertex CEO Jeff Leiden wasn't too concerned about the potential competition from Galapagos and AbbVie when he spoke at the Cowen healthcare conference in March . AbbVie (NYSE: ABBV) , Galapagos' partner, opted not to proceed with the development of a second triple-drug combo that also included GLPG2737. Galapa... | AbbVie (NYSE: ABBV) , Galapagos' partner, opted not to proceed with the development of a second triple-drug combo that also included GLPG2737. Galapagos said that it's "reviewing the future of its CF collaboration with AbbVie." Now what Vertex CEO Jeff Leiden wasn't too concerned about the potential competition from Ga... | AbbVie (NYSE: ABBV) , Galapagos' partner, opted not to proceed with the development of a second triple-drug combo that also included GLPG2737. Galapagos said that it's "reviewing the future of its CF collaboration with AbbVie." Now what Vertex CEO Jeff Leiden wasn't too concerned about the potential competition from Ga... | *Stock Advisor returns as of June 4, 2018 Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. AbbVie (NYSE: ABBV) , Galapagos' partner, opted not to proceed with the development of a second triple-drug combo that also included GLPG2737. Galapagos said that it's "reviewing the future of its CF collaboration... |
25,454 | 2018-06-29 00:00:00 UTC | Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study | ABBV | https://www.nasdaq.com/articles/lillys-lly-taltz-positive-in-ankylosing-spondylitis-study-2018-06-29 | null | null | Pharma giant Eli Lilly and CompanyLLY announced positive top-line results from a second phase III study on its arthritis drug, Taltz (ixekizumab), for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA).
The phase III study, COAST-W, evaluated the safety and effica... | Although many other drugs like Novartis' NVS Cosentyx and AbbVie's ABBV Humira are approved to treat plaque psoriasis, Lilly claims Taltz is now the first and the only FDA approved treatment for genital psoriasis. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): F... | Although many other drugs like Novartis' NVS Cosentyx and AbbVie's ABBV Humira are approved to treat plaque psoriasis, Lilly claims Taltz is now the first and the only FDA approved treatment for genital psoriasis. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): F... | Although many other drugs like Novartis' NVS Cosentyx and AbbVie's ABBV Humira are approved to treat plaque psoriasis, Lilly claims Taltz is now the first and the only FDA approved treatment for genital psoriasis. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): F... | Although many other drugs like Novartis' NVS Cosentyx and AbbVie's ABBV Humira are approved to treat plaque psoriasis, Lilly claims Taltz is now the first and the only FDA approved treatment for genital psoriasis. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): F... |
25,455 | 2018-06-29 00:00:00 UTC | XLV, UNH, MRK, ABBV: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/xlv-unh-mrk-abbv-large-outflows-detected-etf-2018-06-29 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $483.1 million dollar outflow -- that's a 3.1% decrease week over week (from 186,515,324 to 180,715,3... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.6%, Merck & Co Inc (Symbol: MRK) is up about 0.8%, and AbbVie Inc (Symbol: ABBV) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.6%, Merck & Co Inc (Symbol: MRK) is up about 0.8%, and AbbVie Inc (Symbol: ABBV) is higher by about 1.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year ... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.6%, Merck & Co Inc (Symbol: MRK) is up about 0.8%, and AbbVie Inc (Symbol: ABBV) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.6%, Merck & Co Inc (Symbol: MRK) is up about 0.8%, and AbbVie Inc (Symbol: ABBV) is higher by about 1.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year ... |
25,456 | 2018-06-29 00:00:00 UTC | Will a Trade War With China Wreak Havoc in US Healthcare? | ABBV | https://www.nasdaq.com/articles/will-trade-war-china-wreak-havoc-us-healthcare-2018-06-29 | null | null | Ever since President Trump's imposition of tariffs on steel and aluminum imports from China, markets at large have suffered dearly. There have been a number of meetings between trade representatives from both the countries but all in vain.
To further escalate trade-war tensions, reports have surfaced from the U.S. Trea... | Market leaders of the Zacks Large Cap Pharmaceutical Industry such as AbbVie ABBV , GlaxoSmithKline GSK , Eli Lilly LLY , Merck MRK and Pifzer PFE would end up being the biggest losers. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Gl... | Market leaders of the Zacks Large Cap Pharmaceutical Industry such as AbbVie ABBV , GlaxoSmithKline GSK , Eli Lilly LLY , Merck MRK and Pifzer PFE would end up being the biggest losers. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Gl... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com c... | Market leaders of the Zacks Large Cap Pharmaceutical Industry such as AbbVie ABBV , GlaxoSmithKline GSK , Eli Lilly LLY , Merck MRK and Pifzer PFE would end up being the biggest losers. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Gl... |
25,457 | 2018-06-29 00:00:00 UTC | Bad News Delivers a Decisive Blow to Galapagos N.V. | ABBV | https://www.nasdaq.com/articles/bad-news-delivers-decisive-blow-galapagos-nv-2018-06-29 | null | null | Galapagos N.V. (NASDAQ: GLPG) is developing new triplet combination therapies with AbbVie (NYSE: ABBV) for cystic fibrosis that the two companies hope can challengeVertex Pharmaceuticals (NASDAQ: VRTX) someday. Unfortunately, the results reported yesterday from a mid-stage study did not inspire confidence. Is Galapagos... | Galapagos N.V. (NASDAQ: GLPG) is developing new triplet combination therapies with AbbVie (NYSE: ABBV) for cystic fibrosis that the two companies hope can challengeVertex Pharmaceuticals (NASDAQ: VRTX) someday. Galapagos stumbles Under a 2013 that was expanded in 2016, AbbVie is helping Galapagos develop multidrug comb... | Galapagos N.V. (NASDAQ: GLPG) is developing new triplet combination therapies with AbbVie (NYSE: ABBV) for cystic fibrosis that the two companies hope can challengeVertex Pharmaceuticals (NASDAQ: VRTX) someday. Galapagos stumbles Under a 2013 that was expanded in 2016, AbbVie is helping Galapagos develop multidrug comb... | Galapagos stumbles Under a 2013 that was expanded in 2016, AbbVie is helping Galapagos develop multidrug combination therapies to improve the transport of chloride for up to 90% of cystic fibrosis patients. Galapagos N.V. (NASDAQ: GLPG) is developing new triplet combination therapies with AbbVie (NYSE: ABBV) for cystic... | Galapagos stumbles Under a 2013 that was expanded in 2016, AbbVie is helping Galapagos develop multidrug combination therapies to improve the transport of chloride for up to 90% of cystic fibrosis patients. Galapagos N.V. (NASDAQ: GLPG) is developing new triplet combination therapies with AbbVie (NYSE: ABBV) for cystic... |
25,458 | 2018-06-29 00:00:00 UTC | Should Value Investors Consider AbbVie (ABBV) Stock Now? | ABBV | https://www.nasdaq.com/articles/should-value-investors-consider-abbvie-abbv-stock-now-2018-06-29 | null | null | Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking ... | In particular, it is worth noting that the company has a Growth grade of B and a Momentum score of C. This gives ABBV a Zacks VGM score-or its overarching fundamental grade-of A. Bottom Line AbbVie is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Let's ... | If we focus on the long-term PE trend, AbbVie's current PE level puts it slightly below its midpoint over the past five years. You can see the consensus estimate trend and recent price action for the stock in the chart below: AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote This favor... | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. Y... | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. O... |
25,459 | 2018-06-27 00:00:00 UTC | AbbVie (ABBV), Calico Extend R&D Deal, to Invest $500M Each | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-calico-extend-rd-deal-to-invest-%24500m-each-2018-06-27 | null | null | AbbVie, Inc.ABBV announced extension of its 2014 research and development (R&D) agreement with Calico Life Sciences to jointly discover and develop candidates to treat age-related diseases including neurodegeneration and cancer.
Calico is a San Francisco Bay Area based biotech company, backed by Alphabet Inc. GOOGL . S... | AbbVie will continue to support Calico in early R&D stages and will have the option to manage late-stage development and commercial activities. AbbVie, Inc.ABBV announced extension of its 2014 research and development (R&D) agreement with Calico Life Sciences to jointly discover and develop candidates to treat age-rela... | AbbVie is also studying chronic lymphocytic leukemia (CLL) drug Venclyxto/Venclexta to expand the label to address the broader relapsed/refractory CLL patient population, expand into earlier lines of therapy and other hematologic malignancies like multiple myeloma and AML. Click to get this free report Alphabet Inc. (G... | Imbruvica, currently approved for quite a few indications, has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases. AbbVie is also studying chronic lymphocytic leukemia (CLL) drug Venclyxto/Venclexta to expand the label to address th... | AbbVie, Inc.ABBV announced extension of its 2014 research and development (R&D) agreement with Calico Life Sciences to jointly discover and develop candidates to treat age-related diseases including neurodegeneration and cancer. AbbVie will continue to support Calico in early R&D stages and will have the option to mana... |
25,460 | 2018-06-27 00:00:00 UTC | 3 Biotech Stocks With Major Potential Catalysts in July | ABBV | https://www.nasdaq.com/articles/3-biotech-stocks-major-potential-catalysts-july-2018-06-27 | null | null | When you think of July, visions of fireworks might come to mind. Three biotechs -- and a big partner for one of them -- are especially hoping to see some fireworks next month.
Neurocrine Biosciences (NASDAQ: NBIX) , along with partner AbbVie (NYSE: ABBV) , Progenics Pharmaceuticals (NASDAQ: PGNX) , and Insys Pharmaceut... | Neurocrine Biosciences (NASDAQ: NBIX) , along with partner AbbVie (NYSE: ABBV) , Progenics Pharmaceuticals (NASDAQ: PGNX) , and Insys Pharmaceuticals (NASDAQ: INSY) await major approval decisions by the U.S. Food and Drug Administration (FDA). Neurocrine Biosciences (and AbbVie) Neurocrine Biosciences originally develo... | Neurocrine Biosciences (NASDAQ: NBIX) , along with partner AbbVie (NYSE: ABBV) , Progenics Pharmaceuticals (NASDAQ: PGNX) , and Insys Pharmaceuticals (NASDAQ: INSY) await major approval decisions by the U.S. Food and Drug Administration (FDA). Neurocrine Biosciences (and AbbVie) Neurocrine Biosciences originally develo... | Neurocrine Biosciences (NASDAQ: NBIX) , along with partner AbbVie (NYSE: ABBV) , Progenics Pharmaceuticals (NASDAQ: PGNX) , and Insys Pharmaceuticals (NASDAQ: INSY) await major approval decisions by the U.S. Food and Drug Administration (FDA). However, an approval for Azedra would mean more to Progenics than an approva... | However, an approval for Azedra would mean more to Progenics than an approval of elagolix would mean for Neurocrine, and certainly more than it would mean for AbbVie. Neurocrine Biosciences (NASDAQ: NBIX) , along with partner AbbVie (NYSE: ABBV) , Progenics Pharmaceuticals (NASDAQ: PGNX) , and Insys Pharmaceuticals (NA... |
25,461 | 2018-06-26 00:00:00 UTC | Oversold Conditions For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/oversold-conditions-abbvie-abbv-2018-06-26 | null | null | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... | In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.8, after changing hands as low as $92.49 per share. A bullish investor could look at ABBV's 29.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and ... | The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $69.38 per share, with $125.86 as the 52 week high point - that compares with a last trade of $92.30. In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold terri... | In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.8, after changing hands as low as $92.49 per share. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $69.38 per shar... | In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 29.8, after changing hands as low as $92.49 per share. A bullish investor could look at ABBV's 29.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and ... |
25,462 | 2018-06-26 00:00:00 UTC | AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-imbruvica-snda-gets-priority-review-from-fda-2018-06-26 | null | null | AbbVie Inc. ABBV announced that the FDA has granted a priority review to its lymphoma drug Imbruvica's (ibrutinib) sNDA for the treatment of Waldenström's macroglobulinemia (WM) in combination with Rituxan (rituximab), marketed by Genentech, a subsidiary of Roche Group RHHBY .
The sNDA was based on positive data from t... | AbbVie Inc. ABBV announced that the FDA has granted a priority review to its lymphoma drug Imbruvica's (ibrutinib) sNDA for the treatment of Waldenström's macroglobulinemia (WM) in combination with Rituxan (rituximab), marketed by Genentech, a subsidiary of Roche Group RHHBY . The drug is being jointly developed and ma... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV announced that the FDA h... | AbbVie Inc. ABBV announced that the FDA has granted a priority review to its lymphoma drug Imbruvica's (ibrutinib) sNDA for the treatment of Waldenström's macroglobulinemia (WM) in combination with Rituxan (rituximab), marketed by Genentech, a subsidiary of Roche Group RHHBY . Click to get this free report Roche Holdin... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV announced that the FDA h... |
25,463 | 2018-06-26 00:00:00 UTC | Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection | ABBV | https://www.nasdaq.com/articles/gileads-gild-biktarvy-gets-ec-nod-for-hiv-1-infection-2018-06-26 | null | null | Gilead Sciences, Inc . GILD announced that the European Commission has granted Marketing Authorization to HIV combination therapy Biktarvy (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF).
Biktarvy is approved as a once-daily single tablet regimen (STR) for the treatment of HIV-1 infecti... | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Mayret, and Merck's MRK Zepatier among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Rep... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and ... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and ... | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Mayret, and Merck's MRK Zepatier among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Rep... |
25,464 | 2018-06-25 00:00:00 UTC | The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, IBM, McDonald's and General Electric | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-procter-gamble-abbvie-ibm-mcdonalds-and-general | null | null | For Immediate Release
Chicago, IL - June 25, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Procter & Gamble PG , AbbVie A... | Stocks recently featured in the blog include Procter & Gamble PG , AbbVie ABBV , IBM IBM , McDonald's MCD and General Electric GE . Here are highlights from Friday's Analyst Blog: Top Research Reports for Procter & Gamble, AbbVie and IBM The Zacks Research Daily presents the best research output of our analyst team. To... | Stocks recently featured in the blog include Procter & Gamble PG , AbbVie ABBV , IBM IBM , McDonald's MCD and General Electric GE . Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble, AbbVie and IBM. Click to get this free report International Business Machines Corporati... | Here are highlights from Friday's Analyst Blog: Top Research Reports for Procter & Gamble, AbbVie and IBM The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble, AbbVie and IBM. Click to get this... | Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble, AbbVie and IBM. Stocks recently featured in the blog include Procter & Gamble PG , AbbVie ABBV , IBM IBM , McDonald's MCD and General Electric GE . Here are highlights from Friday's Analyst Blog: Top Research Reports fo... |
25,465 | 2018-06-25 00:00:00 UTC | Monday 6/25 Insider Buying Report: DOVA, ABBV | ABBV | https://www.nasdaq.com/articles/monday-625-insider-buying-report-dova-abbv-2018-06-25 | null | null | As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy - they expect to make money. So let's look at two noteworthy recent insider buys.
On Thursday, Dova Pharmaceuticals' Director, Steven M. Goldman, made a $151,100 purchase of DOVA, buying 5,000 shares at a cost... | And at AbbVie, there was insider buying on Wednesday, by Director Edward J. Rapp who purchased 1,013 shares for a cost of $98.63 each, for a trade totaling $99,909. AbbVie Inc is trading off about 0.7% on the day Monday. Investors have the opportunity to pick up ABBV at a price even lower than Rapp did, with the stock ... | VIDEO: Monday 6/25 Insider Buying Report: DOVA, ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And at AbbVie, there was insider buying on Wednesday, by Director Edward J. Rapp who purchased 1,013 shares for a cost of $98.63 each... | VIDEO: Monday 6/25 Insider Buying Report: DOVA, ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And at AbbVie, there was insider buying on Wednesday, by Director Edward J. Rapp who purchased 1,013 shares for a cost of $98.63 each... | And at AbbVie, there was insider buying on Wednesday, by Director Edward J. Rapp who purchased 1,013 shares for a cost of $98.63 each, for a trade totaling $99,909. AbbVie Inc is trading off about 0.7% on the day Monday. Investors have the opportunity to pick up ABBV at a price even lower than Rapp did, with the stock ... |
25,466 | 2018-06-21 00:00:00 UTC | ABBV Dividend Yield Pushes Past 4% | ABBV | https://www.nasdaq.com/articles/abbv-dividend-yield-pushes-past-4-2018-06-21 | null | null | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $3.84), with the stock changing hands as low as $95.26 on the day. Dividends are particularly important for investor... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $3.84), with the stock changing hands as low as $95.26 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $3.84), with the stock changing hands as low as $95.26 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $3.84), with the stock changing hands as low as $95.26 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $3.84), with the stock changing hands as low as $95.26 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... |
25,467 | 2018-06-21 00:00:00 UTC | XLV, ABBV, AMGN, MDT: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/xlv-abbv-amgn-mdt-etf-outflow-alert-2018-06-21 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $80.8 million dollar outflow -- that's a 0.5% decrease week over week (from 187,465,324 to 186,515,32... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.3%, Amgen Inc (Symbol: AMGN) is down about 0.8%, and Medtronic PLC (Symbol: MDT) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.3%, Amgen Inc (Symbol: AMGN) is down about 0.8%, and Medtronic PLC (Symbol: MDT) is up by about 0.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.3%, Amgen Inc (Symbol: AMGN) is down about 0.8%, and Medtronic PLC (Symbol: MDT) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.3%, Amgen Inc (Symbol: AMGN) is down about 0.8%, and Medtronic PLC (Symbol: MDT) is up by about 0.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price perform... |
25,468 | 2018-06-20 00:00:00 UTC | 5 Experimental New Drugs That Could Be Worth $47 Billion | ABBV | https://www.nasdaq.com/articles/5-experimental-new-drugs-could-be-worth-47-billion-2018-06-20 | null | null | Dollars today are worth a whole lot more than dollars you might receive a few years from now, so when a relatively conservative market research provider pins an 11-digit net present value to a drug still in development, it pays to understand why.
Every year, EvaluatePharma ranks experimental drugs in development based ... | Upadacitinib from AbbVie AbbVie Inc. 's (NYSE: ABBV) flagship rheumatoid arthritis (RA) treatment is the world's best-selling drug today, and its next addition to this space could be worth $9.9 billion. AbbVie intends to submit an application for the treatment of RA before the end of 2018 with a possible launch slated ... | Upadacitinib from AbbVie AbbVie Inc. 's (NYSE: ABBV) flagship rheumatoid arthritis (RA) treatment is the world's best-selling drug today, and its next addition to this space could be worth $9.9 billion. AbbVie intends to submit an application for the treatment of RA before the end of 2018 with a possible launch slated ... | Upadacitinib from AbbVie AbbVie Inc. 's (NYSE: ABBV) flagship rheumatoid arthritis (RA) treatment is the world's best-selling drug today, and its next addition to this space could be worth $9.9 billion. AbbVie intends to submit an application for the treatment of RA before the end of 2018 with a possible launch slated ... | Upadacitinib from AbbVie AbbVie Inc. 's (NYSE: ABBV) flagship rheumatoid arthritis (RA) treatment is the world's best-selling drug today, and its next addition to this space could be worth $9.9 billion. AbbVie intends to submit an application for the treatment of RA before the end of 2018 with a possible launch slated ... |
25,469 | 2018-06-20 00:00:00 UTC | Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks | ABBV | https://www.nasdaq.com/articles/forget-johnson-johnson-here-are-2-better-dividend-stocks-2018-06-20 | null | null | If you own Johnson & Johnson (NYSE: JNJ) stock, there's a really good chance that you do so because of its dividend. The healthcare giant is a longtime favorite for income investors, in large part due to its sterling track record of 56 consecutive years of dividend increases.
But if you really prioritize dividend payme... | When it comes to dividends, I think investors should look to AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) instead of J&J. A lot to offer AbbVie is a rarity in that it has something to offer to nearly every kind of investor. AbbVie also has a long track record of dividend increases. | When it comes to dividends, I think investors should look to AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) instead of J&J. A lot to offer AbbVie is a rarity in that it has something to offer to nearly every kind of investor. AbbVie also has a long track record of dividend increases. | Wall Street analysts project that AbbVie will increase its earnings by nearly 17% annually over the next five years -- more than double the expected earnings growth for Johnson & Johnson. When it comes to dividends, I think investors should look to AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) instead of J&J. A lot to off... | Wall Street analysts project that AbbVie will increase its earnings by nearly 17% annually over the next five years -- more than double the expected earnings growth for Johnson & Johnson. And while Pfizer's dividend increases of 42% over the last five years aren't as impressive as AbbVie's, the big drugmaker still beat... |
25,470 | 2018-06-19 00:00:00 UTC | Agree To Purchase AbbVie At $55, Earn 3.2% Using Options | ABBV | https://www.nasdaq.com/articles/agree-purchase-abbvie-55-earn-32-using-options-2018-06-19 | null | null | Investors considering a purchase of AbbVie Inc (Symbol: ABBV) shares, but tentative about paying the going market price of $98.19/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2020 put at the $55 strike, ... | Investors considering a purchase of AbbVie Inc (Symbol: ABBV) shares, but tentative about paying the going market price of $98.19/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and ... | Selling a put does not give an investor access to ABBV's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the... | Selling a put does not give an investor access to ABBV's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the... | Investors considering a purchase of AbbVie Inc (Symbol: ABBV) shares, but tentative about paying the going market price of $98.19/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and ... |
25,471 | 2018-06-18 00:00:00 UTC | Bristol-Myers Posts Data on Empliciti, China Approves Opdivo | ABBV | https://www.nasdaq.com/articles/bristol-myers-posts-data-on-empliciti-china-approves-opdivo-2018-06-18 | null | null | Bristol-Myers Squibb CompanyBMY announced positive results from the phase II study, ELOQUENT-3, on oncology drug, Empliciti.
The study is evaluating the addition of Empliciti to Pomalyst and low-dose dexamethasone (EPd) in patients with relapsed/refractory multiple myeloma (RRMM). The international study is evaluating ... | Bristol-Myers is co-developing Empliciti with AbbVie ABBV . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this ar... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers is co-developin... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers is co-developin... | Bristol-Myers is co-developing Empliciti with AbbVie ABBV . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this ar... |
25,472 | 2018-06-17 00:00:00 UTC | Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming | ABBV | https://www.nasdaq.com/articles/big-pharma-stock-investors-beware-another-250-billion-patent-cliff-coming-2018-06-17 | null | null | Just as big pharma companies were finally getting over the patent cliff from a few years ago, another one is on the way.
Market research firm EvaluatePharma projects that more than $250 billion in sales are at risk between 2018 and 2024 for drugs that will lose patent exclusivity. Four companies could especially feel t... | *Stock Advisor returns as of June 4, 2018 Keith Speights owns shares of AbbVie, Celgene, and Pfizer. Four companies could especially feel the sting from these losses: AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , Johnson & Johnson (NYSE: JNJ) , and Novo Nordisk (NYSE: NVO) . AbbVie reported sales of $18.4 billion for ... | Four companies could especially feel the sting from these losses: AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , Johnson & Johnson (NYSE: JNJ) , and Novo Nordisk (NYSE: NVO) . AbbVie reported sales of $18.4 billion for the autoimmune disease drug last year. Although a key U.S. patent for Humira expired in 2016, AbbVie ... | Although a key U.S. patent for Humira expired in 2016, AbbVie has other patents that protect the drug through 2022. Four companies could especially feel the sting from these losses: AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , Johnson & Johnson (NYSE: JNJ) , and Novo Nordisk (NYSE: NVO) . AbbVie reported sales of $18... | Four companies could especially feel the sting from these losses: AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , Johnson & Johnson (NYSE: JNJ) , and Novo Nordisk (NYSE: NVO) . AbbVie reported sales of $18.4 billion for the autoimmune disease drug last year. Although a key U.S. patent for Humira expired in 2016, AbbVie ... |
25,473 | 2018-06-15 00:00:00 UTC | 3 High-Yield Stocks at Rock-Bottom Prices | ABBV | https://www.nasdaq.com/articles/3-high-yield-stocks-rock-bottom-prices-2018-06-15 | null | null | Finding stocks that offer up a high yield and are trading at a bargain price isn't easy, but there are a few of them floating around. Knowing that, we asked a team of investors to each highlight a dividend stock with a big yield that is currently trading at a rock-bottom price. Here's why they called out AbbVie (NYSE: ... | Here's why they called out AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and Retail Opportunity Investment Corp (NASDAQ: ROIC) . Income, value, and growth -- this big pharma has it all Keith Speights (AbbVie): Impeccable. That's probably the best way to describe AbbVie's credentials as a divide... | Here's why they called out AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and Retail Opportunity Investment Corp (NASDAQ: ROIC) . Income, value, and growth -- this big pharma has it all Keith Speights (AbbVie): Impeccable. That's probably the best way to describe AbbVie's credentials as a divide... | Here's why they called out AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and Retail Opportunity Investment Corp (NASDAQ: ROIC) . Income, value, and growth -- this big pharma has it all Keith Speights (AbbVie): Impeccable. That's probably the best way to describe AbbVie's credentials as a divide... | AbbVie's dividend currently yields more than 3.7%. Here's why they called out AbbVie (NYSE: ABBV) , Brookfield Infrastructure Partners (NYSE: BIP) , and Retail Opportunity Investment Corp (NASDAQ: ROIC) . Income, value, and growth -- this big pharma has it all Keith Speights (AbbVie): Impeccable. |
25,474 | 2018-06-15 00:00:00 UTC | Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR | ABBV | https://www.nasdaq.com/articles/daily-dividend-report-vici-wpc-abbv-bmy-eqr-2018-06-15 | null | null | VICI Properties ( VICI ) has declared a regular quarterly cash dividend of $0.2625 per share of common stock for the period from April 1, 2018 to June 30, 2018. The dividend will be payable on July 13, 2018 to stockholders of record as of the close of business on June 28, 2018.
W. P. Carey ( WPC ) increased its quarter... | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bristol-Myers Squibb Company ( BMY ) declared a quarterly d... | VIDEO: Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VICI Properties ( VICI ) has declared a regular quarterly c... | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. VICI Properties ( VICI ) has declared a regular quarterly c... | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. VICI Properties ( VICI ) has declared a regular quarterly c... |
25,475 | 2018-06-15 00:00:00 UTC | Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-glaxosmithkline-plc-2018-06-15 | null | null | If you only looked at stock performance for 2018, GlaxoSmithKline plc (NYSE: GSK) would seem to be in much better shape than AbbVie Inc. (NYSE: ABBV) . GSK stock is up nearly 20% year to date, while AbbVie's share price isn't much higher than it was at the beginning of the year. 2017 was a different story, though, with... | Overall, Wall Street analysts project that AbbVie's current and forthcoming products will enable the drugmaker to grow earnings by an average of nearly 17% annually over the next five years. If you only looked at stock performance for 2018, GlaxoSmithKline plc (NYSE: GSK) would seem to be in much better shape than AbbV... | The case for AbbVie AbbVie claims the top-selling drug in the world -- Humira. AbbVie's dividend currently yields 3.73%, and the big pharma company has boosted the dividend payout by 140% over the last five years. If you only looked at stock performance for 2018, GlaxoSmithKline plc (NYSE: GSK) would seem to be in much... | GSK stock is up nearly 20% year to date, while AbbVie's share price isn't much higher than it was at the beginning of the year. The case for AbbVie AbbVie claims the top-selling drug in the world -- Humira. Two of AbbVie's other products, hepatitis C drug Mavyret and cancer drug Venclexta, are expected to rank in the 5... | GSK stock is up nearly 20% year to date, while AbbVie's share price isn't much higher than it was at the beginning of the year. If you only looked at stock performance for 2018, GlaxoSmithKline plc (NYSE: GSK) would seem to be in much better shape than AbbVie Inc. (NYSE: ABBV) . 2017 was a different story, though, with... |
25,476 | 2018-06-13 00:00:00 UTC | ABBV Makes Notable Cross Below Critical Moving Average | ABBV | https://www.nasdaq.com/articles/abbv-makes-notable-cross-below-critical-moving-average-2018-06-13 | null | null | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $98.60, changing hands as low as $97.86 per share. AbbVie Inc shares are currently trading down about 0.6% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $98.60, changing hands as low as $97.86 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week rang... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $98.60, changing hands as low as $97.86 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week rang... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $98.60, changing hands as low as $97.86 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week rang... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $98.60, changing hands as low as $97.86 per share. AbbVie Inc shares are currently trading down about 0.6% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... |
25,477 | 2018-06-13 00:00:00 UTC | Notable ETF Inflow Detected - XLV, ABBV, AMGN, MDT | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-abbv-amgn-mdt-2018-06-13 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $298.0 million dollar inflow -- that's a 1.9% increase week over week in outstanding units (from 183,... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Amgen Inc (Symbol: AMGN) is trading flat, and Medtronic PLC (Symbol: MDT) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Amgen Inc (Symbol: AMGN) is trading flat, and Medtronic PLC (Symbol: MDT) is lower by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price perform... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Amgen Inc (Symbol: AMGN) is trading flat, and Medtronic PLC (Symbol: MDT) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Amgen Inc (Symbol: AMGN) is trading flat, and Medtronic PLC (Symbol: MDT) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , ... |
25,478 | 2018-06-13 00:00:00 UTC | Humira's Sales Will Decline -- and It's Fantastic News for AbbVie | ABBV | https://www.nasdaq.com/articles/humiras-sales-will-decline-and-its-fantastic-news-abbvie-2018-06-13 | null | null | Can bad news be good news? For AbbVie (NYSE: ABBV) , it can.
The company's top-selling drug, Humira, will begin to face biosimilar competition in Europe later this year. In early 2023, biosimilars to Humira will hit the U.S. market. There's no doubt that sales for the drug will decline over the next few years. That's t... | Buying time These projections from EvaluatePharma confirm how good the deal with Amgen made last September really was for AbbVie. AbbVie will certainly have bad news on the way once biosimilar rivals begin taking a bite out of Humira's market share. For AbbVie (NYSE: ABBV) , it can. | However, that total includes revenue made by AbbVie and Johnson & Johnson . For AbbVie (NYSE: ABBV) , it can. But it's also good news for AbbVie. | Humira of the future In 2017, AbbVie reported Humira sales of $18.4 billion. Even with falling sales for Humira, though, AbbVie expects the drug to generate significant cash flow throughout the next decade. For AbbVie (NYSE: ABBV) , it can. | Humira of the future In 2017, AbbVie reported Humira sales of $18.4 billion. For AbbVie (NYSE: ABBV) , it can. But it's also good news for AbbVie. |
25,479 | 2018-06-11 00:00:00 UTC | Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval | ABBV | https://www.nasdaq.com/articles/abbvie-roches-leukemia-drugs-combination-gets-fda-approval-2018-06-11 | null | null | AbbVie, Inc.ABBV announced that the FDA has granted approval for the combination use of its cancer drug Venclexta and Roche's RHHBY Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at ... | Also, this summer, AbbVie will file a regulatory application in the United States for Venclexta in acute myeloid leukemia (AML) while a phase III program in multiple myeloma is also progressing well. AbbVie, Inc.ABBV announced that the FDA has granted approval for the combination use of its cancer drug Venclexta and Ro... | AbbVie, Inc.ABBV announced that the FDA has granted approval for the combination use of its cancer drug Venclexta and Roche's RHHBY Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at ... | AbbVie, Inc.ABBV announced that the FDA has granted approval for the combination use of its cancer drug Venclexta and Roche's RHHBY Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at ... | AbbVie, Inc.ABBV announced that the FDA has granted approval for the combination use of its cancer drug Venclexta and Roche's RHHBY Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at ... |
25,480 | 2018-06-11 00:00:00 UTC | The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-bristol-myers-merck-roche-lilly-and-abbvie-2018-06-11 | null | null | For Immediate Release
Chicago, IL - June 11, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol Myers BMY , Merck MRK ... | AbbVie presented early data from a phase II study evaluating a combination of its cancer drugs Imbruvica plus Venclexta (venetoclax) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Stocks recently featured in the blog include Bristol Myers BMY , Merck MRK , Roche RHHBY , Lilly LLY and ... | (Read more: Abbvie's Upadacitinib Fifth RA Study Data Positive ) Glaxo Completes Buyout of Novartis' Stake in Consumer Healthcare JV : Glaxo announced that it has completed its previously announced deal to buy out Novartis' 36.5% stake in the Consumer HealthCare joint venture for $13 billion (£9.2 billion), With the ac... | JAK inhibitors were in the news this week with Lilly finally gaining FDA approval for its rheumatoid arthritis ("RA") candidate Olumiant (baricitinib) in the United States while AbbVie presented positive top-line data from its fifth late-stage study on upadacitinib in RA. Click to get this free report Roche Holding AG ... | Stocks recently featured in the blog include Bristol Myers BMY , Merck MRK , Roche RHHBY , Lilly LLY and AbbVie ABBV . JAK inhibitors were in the news this week with Lilly finally gaining FDA approval for its rheumatoid arthritis ("RA") candidate Olumiant (baricitinib) in the United States while AbbVie presented positi... |
25,481 | 2018-06-10 00:00:00 UTC | 3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate | ABBV | https://www.nasdaq.com/articles/3-reasons-expect-smooth-sailing-abbvies-mission-critical-candidate-2018-06-10 | null | null | As one of the world's largest drugmakers, AbbVie Inc. (NYSE: ABBV) is made of many moving pieces. The big one at the top, Humira, can't keep growing forever. In fact, its main U.S. patent has already expired.
Luckily, a key component of the company's Humira replacement strategy is firing on all cylinders. Upadacitinib ... | Upadacitinib hit the mark again AbbVie's rheumatoid arthritis (RA) candidate recently passed its fifth pivotal trial designed to support new drug applications to be submitted later this year. As one of the world's largest drugmakers, AbbVie Inc. (NYSE: ABBV) is made of many moving pieces. Given this huge population wit... | Upadacitinib hit the mark again AbbVie's rheumatoid arthritis (RA) candidate recently passed its fifth pivotal trial designed to support new drug applications to be submitted later this year. Although it looks like smooth sailing ahead, AbbVie investors need to brace themselves for an unfortunate ruling. As one of the ... | Upadacitinib hit the mark again AbbVie's rheumatoid arthritis (RA) candidate recently passed its fifth pivotal trial designed to support new drug applications to be submitted later this year. Incyte and Lilly's main problem is a lack of evidence to convince regulators that Olumiant wasn't responsible, but that probably... | As one of the world's largest drugmakers, AbbVie Inc. (NYSE: ABBV) is made of many moving pieces. Upadacitinib hit the mark again AbbVie's rheumatoid arthritis (RA) candidate recently passed its fifth pivotal trial designed to support new drug applications to be submitted later this year. Given this huge population wit... |
25,482 | 2018-06-07 00:00:00 UTC | Should You Stick With Gilead Sciences? | ABBV | https://www.nasdaq.com/articles/should-you-stick-gilead-sciences-2018-06-07 | null | null | Waning demand for Gilead Sciences ' (NASDAQ: GILD) once-revolutionary hepatitis C drugs has made it one of biopharma's worst performers since 2015, and demand isn't going to improve anytime soon. Should Gilead Sciences shareholders throw the towel, or is this a beat-up bargain that's worth buying?
In this episode of In... | Plus, when you add in competition, primarily from AbbVie (NYSE: ABBV) , for example, AbbVie just released a drug called Mavyret, which is the first treatment that treats all different types of hepatitis C. Previously, you had different drugs for the different genotypes. It's my impression that AbbVie is going to contin... | Plus, when you add in competition, primarily from AbbVie (NYSE: ABBV) , for example, AbbVie just released a drug called Mavyret, which is the first treatment that treats all different types of hepatitis C. Previously, you had different drugs for the different genotypes. It's my impression that AbbVie is going to contin... | Mavyret seems to be the best drug on the market in the indication right now, as evidenced by the fact that it's raking in a couple of billion in sales, and the hepatitis C market share is shifting away from Gilead Sciences to AbbVie. Plus, when you add in competition, primarily from AbbVie (NYSE: ABBV) , for example, A... | Plus, when you add in competition, primarily from AbbVie (NYSE: ABBV) , for example, AbbVie just released a drug called Mavyret, which is the first treatment that treats all different types of hepatitis C. Previously, you had different drugs for the different genotypes. It's my impression that AbbVie is going to contin... |
25,483 | 2018-06-06 00:00:00 UTC | ASCO Ends: Winners & Losers at the Key Cancer Research Event | ABBV | https://www.nasdaq.com/articles/asco-ends-winners-losers-key-cancer-research-event-2018-06-06 | null | null | The world of cancer research is changing fast. This space is seeing huge developments and companies are taking great strides in treating a variety of cancers.
Cancer research is definitely an exciting area and one that investors will keep a close watch on in the coming years. This is because the disease is one of the l... | AbbVie ABBV presented early data from a phase II study evaluating a combination of its cancer drugs Imbruvica plus Venclexta (venetoclax) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squ... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): F... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): F... | AbbVie ABBV presented early data from a phase II study evaluating a combination of its cancer drugs Imbruvica plus Venclexta (venetoclax) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squ... |
25,484 | 2018-06-06 00:00:00 UTC | Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-upadacitinib-fifth-ra-study-data-positive-2018-06-06 | null | null | AbbVie, Inc.ABBV announced that its investigational oral JAK inhibitor, upadacitinib met all primary as well as secondary endpoints in the fifth phase III study from its SELECT program.
The phase III study, SELECT-EARLY, evaluated the candidate for moderate-to-severe rheumatoid arthritis (RA) in patients who had not be... | AbbVie, Inc.ABBV announced that its investigational oral JAK inhibitor, upadacitinib met all primary as well as secondary endpoints in the fifth phase III study from its SELECT program. AbbVie plans to submit regulatory applications for upadacitinib in rheumatoid arthritis in the second half of the year. Successful dev... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that its inves... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that its inves... | AbbVie, Inc.ABBV announced that its investigational oral JAK inhibitor, upadacitinib met all primary as well as secondary endpoints in the fifth phase III study from its SELECT program. AbbVie plans to submit regulatory applications for upadacitinib in rheumatoid arthritis in the second half of the year. Successful dev... |
25,485 | 2018-06-06 00:00:00 UTC | Gilead Collaborates with Hookipa for HBV and HIV Therapies | ABBV | https://www.nasdaq.com/articles/gilead-collaborates-with-hookipa-for-hbv-and-hiv-therapies-2018-06-06 | null | null | Gilead SciencesGILD entered into a research collaboration and license agreement with Hookipa Biotech AG. Per the agreement, Gilead will own exclusive rights to Hookipa's TheraT and Vaxwave arenavirus vector-based immunization technologies for two major chronic infectious disease indications, hepatitis B virus (HBV) and... | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Mayret, and Merck's MRK Zepatier among others. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis ... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sova... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sova... | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Mayret, and Merck's MRK Zepatier among others. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis ... |
25,486 | 2018-06-06 00:00:00 UTC | 2 Cheap Dividend Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-cheap-dividend-stocks-you-can-buy-right-now-2018-06-06 | null | null | Pay less to get paid more. That's exactly what can happen when you buy solid dividend stocks that trade at bargain prices. But can these kinds of stocks be found? Absolutely.
I think both income-seeking investors and value investors will like AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) . Here's why these are... | AbbVie's new hepatitis C virus (HCV) drug Mavyret stole the limelight in the company's first-quarter update . AbbVie expects to launch two new drugs targeting treatment of autoimmune diseases next year -- risankizumab and upadacitinib. Both companies offer investors attractive valuations, mouth-watering dividends, and ... | I think both income-seeking investors and value investors will like AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) . AbbVie AbbVie definitely checks off the "cheap" box using a couple of valuation metrics. And thanks to strong projected earnings growth, AbbVie's price-to-earnings-to-growth (PEG) ratio is a low ... | Both companies offer investors attractive valuations, mouth-watering dividends, and potential growth, and I think both AbbVie and Gilead Sciences are great stocks to buy right now. I think both income-seeking investors and value investors will like AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) . AbbVie AbbVie ... | Both companies offer investors attractive valuations, mouth-watering dividends, and potential growth, and I think both AbbVie and Gilead Sciences are great stocks to buy right now. I think both income-seeking investors and value investors will like AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) . AbbVie AbbVie ... |
25,487 | 2018-06-04 00:00:00 UTC | Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis | ABBV | https://www.nasdaq.com/articles/eli-lillys-olumiant-gets-fda-nod-for-rheumatoid-arthritis-2018-06-04 | null | null | Eli Lilly and CompanyLLY along with its partner Incyte Corporation INCY announced that the FDA has approved the 2 mg dose of Olumiant (baricitinib) for treating moderately-to-severely active rheumatoid arthritis ("RA"). The once-daily oral JAK inhibitor is approved as monotherapy or in combination with methotrexate for... | It will be available at a price 60% lower than the leading TNF inhibitors approved for RA, which includes AbbVie's ABBV Humira and Amgen's AMGN Enbrel among others. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Fre... | It will be available at a price 60% lower than the leading TNF inhibitors approved for RA, which includes AbbVie's ABBV Humira and Amgen's AMGN Enbrel among others. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Fre... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. It will be available at a price 60% lower... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. It will be available at a price 60% lower... |
25,488 | 2018-06-01 00:00:00 UTC | After Hours Most Active for Jun 1, 2018 : ODP, PRSP, GME, ATUS$, QQQ, OKTA, ABBV, FOXA, GDDY, GM, ZNGA, MSFT | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-jun-1-2018-odp-prsp-gme-atus-qqq-okta-abbv-foxa-gddy-gm-znga-msft | null | null | The NASDAQ 100 After Hours Indicator is down -.74 to 7,083.19. The total After hours volume is currently 89,870,577 shares traded.
The following are the most active stocks for the after hours session :
Office Depot, Inc. ( ODP ) is -0.04 at $2.43, with 48,071,361 shares traded. ODP's current last sale is 86.79% of the ... | The consensus earnings per share forecast is -0.3 per share, which represents a -50 percent increase over the EPS one Year Ago AbbVie Inc. ( ABBV ) is -0.03 at $98.02, with 1,778,546 shares traded. ABBV's current last sale is 86.74% of the target price of $113. The following are the most active stocks for the after hou... | The consensus earnings per share forecast is -0.3 per share, which represents a -50 percent increase over the EPS one Year Ago AbbVie Inc. ( ABBV ) is -0.03 at $98.02, with 1,778,546 shares traded. ABBV's current last sale is 86.74% of the target price of $113. , following a 52-week high recorded in today's regular ses... | The consensus earnings per share forecast is -0.3 per share, which represents a -50 percent increase over the EPS one Year Ago AbbVie Inc. ( ABBV ) is -0.03 at $98.02, with 1,778,546 shares traded. ABBV's current last sale is 86.74% of the target price of $113. The following are the most active stocks for the after hou... | The consensus earnings per share forecast is -0.3 per share, which represents a -50 percent increase over the EPS one Year Ago AbbVie Inc. ( ABBV ) is -0.03 at $98.02, with 1,778,546 shares traded. ABBV's current last sale is 86.74% of the target price of $113. The NASDAQ 100 After Hours Indicator is down -.74 to 7,083... |
25,489 | 2018-06-01 00:00:00 UTC | Solid Month Ends with New Round of Trade Fears | ABBV | https://www.nasdaq.com/articles/solid-month-ends-new-round-trade-fears-2018-06-01 | null | null | Trade war concerns resurfaced on Thursday...but this time it had nothing to do with China. The Trump administration announced that it would be imposing tariffs on steel and aluminum for U.S. allies Canada, Mexico and the EU. The responses from those countries were swift and stern.
The response from the market, though, ... | Today's Portfolio Highlights: Healthcare Innovators: A few downgrades from big brokerage firms had Kevin looking a bit askew at large-cap pharma company AbbVie (ABBV), which was one of this portfolio's earliest buys back in April 2017. Therefore, he sold ABBV on Thursday for a return of more than 51%. Technology Innova... | Today's Portfolio Highlights: Healthcare Innovators: A few downgrades from big brokerage firms had Kevin looking a bit askew at large-cap pharma company AbbVie (ABBV), which was one of this portfolio's earliest buys back in April 2017. Therefore, he sold ABBV on Thursday for a return of more than 51%. "Still, news that... | Today's Portfolio Highlights: Healthcare Innovators: A few downgrades from big brokerage firms had Kevin looking a bit askew at large-cap pharma company AbbVie (ABBV), which was one of this portfolio's earliest buys back in April 2017. Therefore, he sold ABBV on Thursday for a return of more than 51%. This cloud-based ... | Today's Portfolio Highlights: Healthcare Innovators: A few downgrades from big brokerage firms had Kevin looking a bit askew at large-cap pharma company AbbVie (ABBV), which was one of this portfolio's earliest buys back in April 2017. Therefore, he sold ABBV on Thursday for a return of more than 51%. The last reading ... |
25,490 | 2018-05-31 00:00:00 UTC | Gilead & Galapagos Announce Positive Data on Filgotinib | ABBV | https://www.nasdaq.com/articles/gilead-galapagos-announce-positive-data-on-filgotinib-2018-05-31 | null | null | Gilead Sciences, Inc . GILD and Galapagos NVGLPG announced that the phase II study, EQUATOR, on pipeline candidate, filgotinib achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16, as assessed by the American College of Rheumatology 20 percent improvement score (ACR20... | We note that Harvoni, Sovaldi and Epclusa face competition from AbbVie's ABBV Viekira Pak and Mayret, and Merck's MRK Zepatier among others. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis ... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclus... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclus... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sovaldi and Epclus... |
25,491 | 2018-05-31 00:00:00 UTC | Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis | ABBV | https://www.nasdaq.com/articles/pfizers-arthritis-drug-gets-fda-nod-for-ulcerative-colitis-2018-05-31 | null | null | Pfizer Inc.PFE announced that the FDA has approved the label expansion of its JAK inhibitor, Xeljanz (tofacitinib), to include a new indication - moderately to severely active ulcerative colitis ("UC"). The drug is approved for the treatment of adult patients with recommended a dose of 10 mg twice-daily for at least ei... | However, there are several blockbuster drugs in the inflammatory segment approved for UC, which includes Johnson & Johnson's JNJ Remicade and Simponi, AbbVie's ABBV Humira and Shire's SHPG Lialda. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Re... | However, there are several blockbuster drugs in the inflammatory segment approved for UC, which includes Johnson & Johnson's JNJ Remicade and Simponi, AbbVie's ABBV Humira and Shire's SHPG Lialda. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Re... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. However, there are several blockbuster drugs in the in... | However, there are several blockbuster drugs in the inflammatory segment approved for UC, which includes Johnson & Johnson's JNJ Remicade and Simponi, AbbVie's ABBV Humira and Shire's SHPG Lialda. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Re... |
25,492 | 2018-05-31 00:00:00 UTC | Thursday’s Vital Data: Micron Technology, Inc. (MU), Bank of America Corp (BAC) and AbbVie Inc. (ABBV) | ABBV | https://www.nasdaq.com/articles/thursdays-vital-data-micron-technology-inc-mu-bank-america-corp-bac-and-abbvie-inc-abbv | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
U.S. stock futures are trading mixed this morning. Renewed trade war fears are limiting Wall Street's upside, as traders look to close out May on a largely positive note.
Political uncertainty in Italy remains a top concern, while the White House could anno... | Finally, AbbVie Inc. (NASDAQ: ABBV ) put volume rolled in following a Credit Suisse downgrade. AbbVie Inc. (ABBV) AbbVie stock largely ignored a bearish research note from Credit Suisse yesterday . The ratings firm cut ABBV stock to "underperform" and dropped its price target to $89 from $104. | AbbVie Inc. (ABBV) AbbVie stock largely ignored a bearish research note from Credit Suisse yesterday . Finally, AbbVie Inc. (NASDAQ: ABBV ) put volume rolled in following a Credit Suisse downgrade. The ratings firm cut ABBV stock to "underperform" and dropped its price target to $89 from $104. | More From InvestorPlace The 7 Best Long-Term Stocks for Risk-Off Investors 3 U.S. Stocks to Buy as International Growth Slows 25 Unstoppable Stocks to Buy No Matter What 3 Cheapest Stocks With Greatest Potential for Growth Compare Brokers The post Thursday's Vital Data: Micron Technology, Inc. (MU), Bank of America Cor... | AbbVie Inc. (ABBV) AbbVie stock largely ignored a bearish research note from Credit Suisse yesterday . Finally, AbbVie Inc. (NASDAQ: ABBV ) put volume rolled in following a Credit Suisse downgrade. The ratings firm cut ABBV stock to "underperform" and dropped its price target to $89 from $104. |
25,493 | 2018-05-30 00:00:00 UTC | AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why | ABBV | https://www.nasdaq.com/articles/astrazeneca-azn-stock-on-growth-path-this-year%3A-heres-why-2018-05-30 | null | null | Shares of AstraZeneca, PLCAZN have risen 4.8% so far this year against the Large-Cap Pharma industry 's decline of 4.9%.
Though the drug sector was off to a strong start in 2018, it has struggled thereafter, probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. Only four l... | Only four large-cap drug stocks have risen this year including AstraZeneca, Merck MRK , AbbVie, Inc. ABBV and Glaxo GSK . Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. ... | Only four large-cap drug stocks have risen this year including AstraZeneca, Merck MRK , AbbVie, Inc. ABBV and Glaxo GSK . Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. ... | Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Only four large-cap drug stocks have rise... | Only four large-cap drug stocks have risen this year including AstraZeneca, Merck MRK , AbbVie, Inc. ABBV and Glaxo GSK . Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. ... |
25,494 | 2018-05-30 00:00:00 UTC | Is AbbVie Inc. (ABBV) a Buy? | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-buy-2018-05-30 | null | null | Let's cut to the chase: Yes, AbbVie Inc. (NYSE: ABBV) stock is a great pick for long-term investors, in my view. The reason why I think the big pharma stock is one to buy is simple: There's a good chance that it will deliver market-beating returns for years to come.
By market-beating returns, I mean a total return of m... | Attractive valuation Earnings growth in the upper teens probably wouldn't be enough to drive AbbVie stock higher faster than the market if its share price was already expensive. Let's cut to the chase: Yes, AbbVie Inc. (NYSE: ABBV) stock is a great pick for long-term investors, in my view. Can AbbVie generate an even h... | Can AbbVie generate an even higher total return over the long run? Let's cut to the chase: Yes, AbbVie Inc. (NYSE: ABBV) stock is a great pick for long-term investors, in my view. A fantastic dividend AbbVie automatically has a head start on topping a 10% average annualized return thanks to its fantastic dividend. | A fantastic dividend AbbVie automatically has a head start on topping a 10% average annualized return thanks to its fantastic dividend. Attractive valuation Earnings growth in the upper teens probably wouldn't be enough to drive AbbVie stock higher faster than the market if its share price was already expensive. While ... | Let's cut to the chase: Yes, AbbVie Inc. (NYSE: ABBV) stock is a great pick for long-term investors, in my view. Of course, just because AbbVie's dividend looks great now doesn't mean that it always will. Can AbbVie generate an even higher total return over the long run? |
25,495 | 2018-05-30 00:00:00 UTC | Noteworthy Wednesday Option Activity: ABBV, GS, DG | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-abbv-gs-dg-2018-05-30 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 137,043 contracts have traded so far, representing approximately 13.7 million underlying shares. That amounts to about 143.8% of ABBV's average daily trading volume over th... | Especially high volume was seen for the $120 strike call option expiring June 08, 2018 , with 31,063 contracts trading so far today, representing approximately 3.1 million underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbo... | Especially high volume was seen for the $120 strike call option expiring June 08, 2018 , with 31,063 contracts trading so far today, representing approximately 3.1 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $120 strike highlighted in orange: Goldma... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 137,043 contracts have traded so far, representing approximately 13.7 million underlying shares. Especially high volume was seen for the $120 strike call option expiring Ju... | Especially high volume was seen for the $120 strike call option expiring June 08, 2018 , with 31,063 contracts trading so far today, representing approximately 3.1 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $120 strike highlighted in orange: Goldma... |
25,496 | 2018-05-30 00:00:00 UTC | Health Care Sector Update for 05/30/2018: ABBV,CTRV,TXMD | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-05302018-abbvctrvtxmd-2018-05-30 | null | null | Top Health Care Stocks
JNJ +1.68%
PFE +1.39%
ABT +1.86%
MRK +2.19%
AMGN +2.26%
Health care stocks were solidly on positive ground Wednesday, including a nearly 1.6% gain for the NYSE Health Care Index in recent trading. Shares of health care companies in the S&P 500 were up almost 1.4% as a group while the Nasdaq Biote... | Among health care stocks moving on news: + AbbVie ( ABBV ) was nearly 3% higher on Wednesday after reporting preliminary results of its modified Dutch auction tender offer, saying it will likely reacquire around 71.4 million of its shares at $105 apiece, equalling about 4.5% of the drugmaker's outstanding shares. Inves... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Among health care stocks moving on news: + AbbVie ( ABBV ) was nearly 3% higher on Wednesday after reporting preliminary results of its modified Dutch auction tender offer, saying it wil... | Among health care stocks moving on news: + AbbVie ( ABBV ) was nearly 3% higher on Wednesday after reporting preliminary results of its modified Dutch auction tender offer, saying it will likely reacquire around 71.4 million of its shares at $105 apiece, equalling about 4.5% of the drugmaker's outstanding shares. Healt... | Among health care stocks moving on news: + AbbVie ( ABBV ) was nearly 3% higher on Wednesday after reporting preliminary results of its modified Dutch auction tender offer, saying it will likely reacquire around 71.4 million of its shares at $105 apiece, equalling about 4.5% of the drugmaker's outstanding shares. Healt... |
25,497 | 2018-05-30 00:00:00 UTC | Health Care Sector Update for 05/30/2018: EXAS,ABBV,CTRV,TXMD | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-05302018-exasabbvctrvtxmd-2018-05-30 | null | null | Top Health Care Stocks
JNJ +1.31%
PFE +1.08%
ABT +1.32%
MRK +2.31%
AMGN +1.95%
Health care stocks were solidly on positive ground Wednesday, including a more than 1.5% gain for the NYSE Health Care Index in recent trade. Also today, shares of health care companies in the S&P 500 were up nearly 1.4% as a group while the... | In other sector news: + AbbVie ( ABBV ) was nearly 3% higher on Wednesday after reporting preliminary results of its modified Dutch auction tender offer, saying it will likely reacquire around 71.4 million of its shares at $105 apiece, equalling about 4.5% of the drugmaker's outstanding shares. Among health care stocks... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news: + AbbVie ( ABBV ) was nearly 3% higher on Wednesday after reporting preliminary results of its modified Dutch auction tender offer, saying it will likely reacquire ... | In other sector news: + AbbVie ( ABBV ) was nearly 3% higher on Wednesday after reporting preliminary results of its modified Dutch auction tender offer, saying it will likely reacquire around 71.4 million of its shares at $105 apiece, equalling about 4.5% of the drugmaker's outstanding shares. Health care stocks were ... | In other sector news: + AbbVie ( ABBV ) was nearly 3% higher on Wednesday after reporting preliminary results of its modified Dutch auction tender offer, saying it will likely reacquire around 71.4 million of its shares at $105 apiece, equalling about 4.5% of the drugmaker's outstanding shares. Health care stocks were ... |
25,498 | 2018-05-29 00:00:00 UTC | What's in Store for Cooper Companies' (COO) Q2 Earnings? | ABBV | https://www.nasdaq.com/articles/whats-in-store-for-cooper-companies-coo-q2-earnings-2018-05-29 | null | null | The Cooper Companies ' COO second-quarter fiscal 2018 results are scheduled to release on Jun 7, after market close. While the core CooperVision (CVI) division is likely to put up a stellar performance, growth across other major segments may also act as catalysts.
In the fiscal first quarter, Cooper Companies posted st... | AbbVie Inc. ABBV has an Earnings ESP of +0.25% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report Ally Financial Inc. (ALLY): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysi... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report Ally Financial Inc. (ALLY): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. A... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report Ally Financial Inc. (ALLY): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. A... | AbbVie Inc. ABBV has an Earnings ESP of +0.25% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report Ally Financial Inc. (ALLY): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysi... |
25,499 | 2018-05-29 00:00:00 UTC | After Hours Most Active for May 29, 2018 : BAC, GE, CSCO, MSFT, JPM, QQQ, ABBV, WFC, SO, QCOM, FOXA, PEP | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-may-29-2018-bac-ge-csco-msft-jpm-qqq-abbv-wfc-so-qcom-foxa-pep | null | null | The NASDAQ 100 After Hours Indicator is up 5.26 to 6,931.8. The total After hours volume is currently 50,131,718 shares traded.
The following are the most active stocks for the after hours session :
Bank of America Corporation ( BAC ) is +0.08 at $29.04, with 2,880,727 shares traded. As reported by Zacks, the current m... | AbbVie Inc. ( ABBV ) is -0.27 at $99.20, with 1,526,349 shares traded. ABBV's current last sale is 87.79% of the target price of $113. The following are the most active stocks for the after hours session : Bank of America Corporation ( BAC ) is +0.08 at $29.04, with 2,880,727 shares traded. | AbbVie Inc. ( ABBV ) is -0.27 at $99.20, with 1,526,349 shares traded. ABBV's current last sale is 87.79% of the target price of $113. Over the last four weeks they have had 12 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2018. | AbbVie Inc. ( ABBV ) is -0.27 at $99.20, with 1,526,349 shares traded. ABBV's current last sale is 87.79% of the target price of $113. Over the last four weeks they have had 12 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2018. | AbbVie Inc. ( ABBV ) is -0.27 at $99.20, with 1,526,349 shares traded. ABBV's current last sale is 87.79% of the target price of $113. Over the last four weeks they have had 12 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2018. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.